

POSTER SESSIONS *Guidelines*

OVERVIEW

Poster sessions are designed to give presenters an opportunity to discuss informally their research with colleagues interested in their research. The purpose of the posters is to visually stimulate interest in the research, to present sufficient information for viewers to understand the methods, results, and significance of the research, and to promote conversations and networking among conference participants.

POSTER SESSION SCHEDULE

Posters will be displayed in the Bordeaux Conference Center Espace Pluriel. Each session is for one day; Session A – Monday, 23 August; Session B – Tuesday, 24 August; and Session C-Wednesday, 25 August.

SET UP: 07:00 to 08:00

All posters must be up by 08:00.

OPEN: Espace Pluriel will be open: 08:00 to 17:00.

DISCUSSION TIME:

Presenters should be by posters between 12:00 and 13:30.

EuroDURG, the European Drug Utilization Research Group, invites all poster presenters displaying their posters on **Tuesday, August 24 (Session B)**, to participate in the **EuroDURG Poster Walk**. EuroDURG will offer presenters the opportunity to present their work and to discuss their results with an audience. Presenters should be at their posters between 12:15 and 13:15. When the poster walk chair and audience stops at your poster, please give a brief, 3-minute presentation and to answer questions about your research. EuroDURG will grant a 'Best Poster Award', offering the winner free registration for the UK-EuroDURG meeting in Northern Ireland in 2005. All meeting participants are invited to join in the walk.

TAKE DOWN: All posters must be taken down by 18:45 on Monday & Tuesday, and by 17:30 on Wednesday. *NOTE:* Neither ISPE or the Bordeaux Conference Center will be responsible for any poster that is left up overnight or is lost or damaged.

NUMBERING SYSTEM

Each poster board will be numbered. The poster number is the first number listed in the final program. Presenters should attach their posters to the board number corresponding to the number assigned to their poster in the final program, which will be available at the registration desk. The **abstract number**, for use in locating abstracts in the final program and the special issue of *Pharmacoepidemiology and Drug Safety*, is in brackets [xxx] after the title of the abstract.

POSTER SPECIFICATIONS

1. Posters must be designed to fit a freestanding poster board 0,93 meters wide by 1,63 meters high (approximately 3'1" wide by 5'4" high). This board will be the only support device available. Business cards or small leaflet literature for distribution may be inserted in an envelope and affixed to the board. Poster orientation: Portrait
2. Posters may be attached to the boards by pushpins or Velcro. Please bring your own mounting supplies.

- 1 **Accuracy of Ramq Medical Services Claims To Identify Episodes of Hospitalizations for Patients with Upper Gastrointestinal Bleeding: A Data Validation Study [79]**
Amir Abbas Tahami Monfared, Elham Rahme, Jacques LeLorier. (Canada)
- 2 **Validity of the General Practice Research Database: A Systematic Review [80]**
W Marieke Schoonen, Andrew J Hall. (United Kingdom)
- 3 **An Algorithm To Extract Medical Codes for Diagnoses from Unstructured Free Text Recorded by General Practitioners in the UK [81]**
Anoop D Shah, Carlos Martinez. (United Kingdom)
- 4 **Disease Comorbidities and Their Pattern of Co-Occurrence Using Practice-Recorded Database: A Cluster Analysis Approach [82]**
Maurille Feudjo-Tepie, Neil S Roskell, John W Logie, Monika Stender. (United Kingdom)
- 5 **A Systematic Approach for Describing Comorbidities Using the UK General Practice Research Database [83]**
Neil S Roskell, John W Logie, Monika Stender, Maurille Feudjo-Tepie. (United Kingdom)
- 6 **The Validity of Electronic Prescription Claims Records: A Comparison of Electronic PBM Claims Records with Pharmacy Provider Derived Records [84]**
Bradley C Martin, Emily R Cox. (United States)
- 7 **The New Generation Pregnancy Exposure Registries [85]**
Deborah L Covington, Peggy A Doi, Melisse Baylor, Hugh Tilson. (United States)
- 8 **Comparison of Different Methods To Calculate Persistence of Drug Use by Using Pharmacy Records [86]**
Boris LG Van Wijk, Olaf H Klungel, Eibert R Heerdink, Anthonius de Boer. (Netherlands)
- 9 **Recent Evidence Surrounding the Efficacy of Protected Carotid Angioplasty with Stents [87]**
Kirsteen R Burton, Thomas Lindsay. (Canada)
- 10 **Accuracy of Inpatient Cardiovascular Diagnoses in a Saskatchewan Health Database [88]**
Suellen M Curkendall, Mary Rose Stang, Judith K Jones, Jean T Barbey, Earl Goehring, Stephan Lanes, Cynthia de Luise. (United States)
- 11 **Did Heat Wave Modify Efficacy of Drugs Prescribed in Patients with Dysautonomia-Related Orthostatic Hypotension during Summer 2003 in France? [89]**
Atul Pathak, Maryse Lapeyre-Mestre, Jean-Louis Montastruc, Jean-Michel Senard. (France)
- 12 **Prognosis of Patients with Atherothrombotic Disease: A Prospective Survey in Non Hospital Setting [90]**
Alain Leizorovicz, Jean Pierre Cambou, Marie Annick Herrman, Jean Ferrieres. (France)
- 13 **Maintenance of Sinus Rhythm in Patients with Atrial Fibrillation: Safety of Flecainide IR and Predictors of Relapses. Epiflec 1 Study [91]**
T Simon, M Mary-Krause, M Thuault, A Chatelin, M Gouin, P Jaillon. (France)
- 14 **Non-Compliance with Antihypertensive Drugs Is Associated with Discontinuation of Antihypertensive Drugs [92]**
Boris LG van Wijk, Olaf H Klungel, Eibert R Heerdink, Anthonius de Boer. (Netherlands)
- 15 **QTc Prolongation in a Healthy Elderly Population and the Risk of Sudden Cardiac Death [93]**
Sabine MJM Straus, Gysele S Bleumink, Cornelis S van der Hooft, Marieke L de Bruin, Jan A Kors, A Hofman, Jacqueline CM Witteman, Bruno HCh Stricker. (Netherlands)
- 16 **Atorvastatin Seems To Perform Better in the Prevention of Cardiovascular Events Than Other Statins [94]**
Jacobus T van Wyk, Jeanne P Dieleman, Hans Dunselman, Marc AM van Wijk, Miriam CJM Sturkenboom. (Netherlands)
- 17 **The Incidence of Ventricular Fibrillation and Ventricular Tachycardia in a Primary Care Population [95]**
Gwenda Hughes, Stephan Rietbrock, Christoph Reiter, Carlos Martinez. (United Kingdom)
- 18 **Cox-2 Selective Inhibitors and Cardiovascular Outcomes in an Elderly Population [96]**
Linda Levesque, James M Brophy, Bin Zhang, Chantal Bourgault. (Canada)
- 19 **Changes in Blood Pressure Lowering Treatment: Do We Reach Treatment Goals? The Tromso Study 1994 AND 2001 [97]**
Anne Elise Eggen, Kristin Svanquist, Inger Njolstad, Frode Skjold. (Norway)
- 20 **Prevalence of Congestive Heart Failure within a Large US Health Insurance Database Using Claims [98]**
Patricia Mona Eng, Kelly Oh, Jennifer Cutone, Dan Fife, Jeff Linder, John Seeger. (United States)
- 21 **Post-Marketing Surveillance for the Safety and Efficacy of Cilnidipine in Patients with Hypertension [99]**
Young Sik Kim, Sung Sunwoo, Hye Ree Lee, Yoo Seock Cheong, Sang Yeoup Lee, Joo Sung Park, Minkwan Rho, Chang Won Won, Korea Post-Marketing Surveillance Research Group. (Republic of Korea)
- 22 **Improved Discharge Planning Following Congestive Heart Failure or Myocardial Infarction Hospitalization Using Computerized Physician Order Entry [100]**
Marie R Griffin, Javed Butler, Patrick G Arbogast, Theodore Speroff, Lemuel R Waitman, Martha Newton, Wayne A Ray. (United States)
- 23 **Over-the-Counter Analgesics' in Ambulatory Pharmacies - Availability and Affordability [101]**
Ilko N Getov, Roza E Evtimova, Zlatka D Dimitrova. (Bulgaria)
- 24 **A Preliminary Study into Pain Perception and Analgesic Usage by Young People [102]**
Ilse Truter. (South Africa)
- 25 **Differences in Use of Non-Prescription Analgesics among Young People with Norwegian and Immigrant Background [103]**
Asgeir Amundsen, Kari Furu, Elin Olaug Rosvold, Espen Bjertness, Svetlana Skurtveit. (Norway)
- 26 **Inhaled Corticosteroids (ICS) and the Risk of Fractures in Children and Adolescents [104]**
Raymond G Schlienger, Susan S Jick, Christoph R Meier. (Switzerland)
- 27 **Safety and Appropriateness of Use of a Low Dose OTC Analgesic: Methodological Issues and Results of a Pharmacy-Based Cohort Study [105]**
Joerg Hasford, Nicholas Moore, Kjetil Hoyer, Ch Milliet, Markus Unkauf, J Magnette. (Germany)
- 28 **Inadequate Prevention of NSAID-Induced Gastrointestinal Events among Long-Term Users of NSAIDs [106]**
Ron MC Herings, Wim G Goettsch. (Netherlands)
- 29 **The Risk of Upper Gastrointestinal Tract Bleeding Associated with Mefenamic Acid in Women of Reproductive Age [107]**
Daniel I Mines, Laura A Novelli. (United States)
- 30 **Risk of Psychiatric Disorder after Paracetamol Poisoning [108]**
Peter Jepsen, Preben B Mortensen, Bente Norgård, Esben Agerbo, Ping Qin, Hendrik Vilstrup, Henrik T Sorensen. (Denmark)
- 31 **Patterns and Predictors of Prescription Narcotic Use among Selected Groups of Patients with Chronic Pain [109]**
Daniel H Solomon, Til Sturmer, Philipp S Wang, George Vaillant, Jerry Avorn. (United States)
- 32 **Non-Steroidal Anti-Inflammatory Drugs and Co-Prescriptions with Gastrointestinal Drugs in Osteoarthritis Patients: A Retrospective Cohort Study [110]**
Giampiero Mazzaglia, Claudio Cricelli, Miriam C Sturkenboom, Pierfrancesco Ruffo, Stefano Giovannoni, Ovidio Brignoli, Achille P Caputi. (Italy)
- 33 **Diclofenac Sodium Induced Sciatic Nerve Damage, a Pharmacoepidemiologic Approach [111]**
Gloria Shalviri, Kheirollah Gholami, Majid Cheraghali, Elahe Kamali, Nazanin Daryabaree. (Islamic Republic of Iran)
- 34 **New Guidelines for Tramadol Usage Following ADRs Reported to Iranian Pharmacovigilance Center [112]**
Kheirollah Gholami, Gloria Shalviri, Elahe Kamali, Nazanin Daryabari, Aida ZARBakhsh. (Islamic Republic of Iran)



- 35 **Quality of Non-Steroidal Anti-Inflammatory Drugs Prescription in the Ambulatory Service in Taiwan** [113]
Yea-Huei Kao Yang, Shu-Wen Jia, Shih-Chen Kuo. (Taiwan)
- 36 **First Line Pharmacotherapy Preferences among Turkish General Practitioners in Pain Management** [114]
Sinem Ezgi Gulmez, Hakan Ergun, Faik Cankat Tulunay. (Turkey)
- 37 **The Risk Benefit Profile of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) as Chemopreventives of Lung Cancer** [115]
Dayin Koopalum, Jeffery A Kotzan, Paul M Dainer, Anand N Vidyashankar, Luke P Naeher, Bradley C Martin. (United States)
- 38 **Undesirable Effects Related with Non-Steroidal Anti-Inflammatory Drugs by the Patients of Portuguese Community Pharmacies** [116]
Ermelindo Fontes, Helder Mota-Filipe, Ana Paula Martins. (Portugal)
- 39 **Cumulative Analgesic Use and Risk of Incident Hypertension in Men** [117]
Tobias Kurth, Til Sturmer, Robert J Glynn, Howard D Sesso, Julie E Buring, J Michael Gaziano. (United States)
- 40 **Liver Disease Associated with Allopurinol: Clinical and Immunological Studies in 7 Cases** [118]
Vasco AJ Maria, Adriana Albuquerque, Rui MM Victorino. (Portugal)
- 41 **Does Mis-Specified Functional Form of a Continuous Variable in Building a Propensity Score Matter?** [119]
Kate L Lapane, Sherry Weitzen. (United States)
- 42 **Comparing Analytic Strategies Using Propensity and Disease Risk Scores: The Example of Nonsteroidal Antiinflammatory Drugs (NSAID) and Short-Term Mortality in the Elderly** [120]
Til Sturmer, Sebastian Schneeweiss, Alan M Brookhart, Kenneth J Rothman, Jerry Avorn, Robert J Glynn. (United States)
- 43 **Identifying Patients with Medication Errors Using the QRESEARCH Database** [121]
Anthony J Avery, Julia Hippisley-Cox, Ronan Ryan, Sarah Armstrong, Caroline J Morris, Judith A Cantrill. (United Kingdom)
- 44 **Pitfalls in Drug Management Systems and Quality of Anti-Tuberculosis Drug in Lower Southern Thailand** [122]
Korngamon Rookkapan, Virasakdi Chongsuvivatwong, Srirat Kasiwong, Saijai Pariyawatee, Yuthichai Kasetcharoen, Petchawan Punggrassami. (Thailand)
- 45 **Trends in Antimicrobials Consumption in a Multi-Profile Hospital in Belarus and Underlying Financial Influences** [123]
Maksim N Mily, Irina M Samsonova, Vladimir Y Lugovoy, Sergey A Golubev. (Sweden)
- 46 **Systematic Reporting of Adverse Events Associated with Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV)-Infected Patients: First Results of a Cooperative Study between the Pharmacovigilance Centre and the Department of Infectious Diseases in Reims, 2002-2003** [124]
Aurelie Molia, Jean-Luc Berger, Christophe Strady, Anne Waldner, Isabelle Beguinot, Christine Rouger, Marie-Laure Germain, Thierry Trenque. (France)
- 47 **Concept of Defined Daily Dose Used for Follow-Up of Hospital Antibiotic Consumption** [125]
Agnes Sommet, Blandine Juillard-Condât, Magalie Baudrant, Philippe Cestac, Maryse Lapyre-Mestre. (France)
- 48 **Evaluation of Total Adipose Mass in HIV Patients Treated by Protease Inhibitors and/or Nucleosidics Analogs** [126]
Neda Tavassoli, Haleh Bagheri, Jean-Louis Montastruc, Jacques Bernard. (France)
- 49 **Antimicrobial Prescribing in Hospitalized Pediatric Patients: A Cross-National Comparison between Marburg (Germany) and Rijeka (Croatia)** [127]
Mike Ufer, Nives Radosevic, Anne Vogt, Goran Palcevski, Igor Francetic, Hanns J Seyberth, Vladimir Ahel, Vera Vlahovic. (Sweden)
- 50 **Antimicrobial Prescribing at a University Hospital: Justified or "Just in Case". Testing a New Scoring System as a Key Quality Indicator** [128]
Vera Vlahovic-Palcevski, Igor Francetic, Goran Palcevski, Srdan Novak, Ulf Bergman. (Croatia)
- 51 **Study of HCV and HBV Infection on Antiretroviral Drug Safety in HIV Patients** [129]
Emmanuelle Guitton, Jean-Louis Montastruc, Haleh Bagheri, Maryse Lapeyre-Mestre. (France)
- 52 **Factors Associated with Self Reported Adverse Events That Have a High or Very High Impact on Every Day Life** [130]
Emmanuelle Guitton, Emmanuel Trenado, Maryse Lapeyre-Mestre. (France)
- 53 **Exploratory Study Using a Record-Linkage Database To Examine Drug Safety in Australia, with Cefaclor as an Example** [131]
John E Marley, Justin J Beilby, Don C Walker, Katherine M Duszynski, Nicole L Pratt, Ian W Boyd, John McEwen. (Australia)
- 54 **A Survey on Drug Utilization Pattern in the Health Care System of India** [132]
Bhagirath K Patel, Mukesh B Nandve, Ramesh K Goyal, Paresh B Shah. (India)
- 55 **Risk of Miscarriage for Pregnant Users of Pivmecillinam** [133]
Mette V Skriver, Mette Norgaard, Lars Pedersen, Henrik T Sorensen. (Denmark)
- 56 **Influence of the Antibiotic Utilization on the Occurrence of Vancomycin-Resistant Enterococci** [134]
Karel Urbanek, Milan Kolar. (Czech Republic)
- 57 **Use of Antimicrobial Surgical Prophylaxis in the Surgical, Gynecologic and Obstetric Interventions of a General Hospital** [135]
Luis E Salazar Domínguez, Elio M Rosete Gamboa, Juan A Furones Mourelles, Lino Aboy Capote. (Cuba)
- 58 **Observational Study on Length of Stay (LOS) and Cost of Antibiotic (AB) Medication in Chronic Obstructive Pulmonary Disease (COPD) Hospital Stays** [136]
Peter Verplanken, Philippe B Van Wilder. (Belgium)
- 59 **Analysis of Antibiotic Use in Belgian Hospitals Using the Minimum Basic Data Set (MBDS)** [137]
Philippe B Van Wilder, Peter Verplanken. (Belgium)
- 60 **Real Use of Anti-Infectives during Ambulant Care in the Federal Republic of Germany Since 1984 - Results of All Pharmacoepidemiological Surveys of the Former Federal Health Office (BGA) and the Robert Koch-Institute -** [138]
Hans-Ulrich W Melchert, Hildtraud Knopf, Ellen Pabel, Marianne Braemer-Hauth. (Germany)
- 61 **Trimethoprim-Sulphamethoxazole Induced Hepatitis: Evidence for an Immunological Mechanism** [139]
Vasco AJ Maria, Adriana Albuquerque, Rui MM Victorino. (Portugal)
- 62 **Antibiotics Use in South Western France Hospitals** [140]
Anne-Marie Rogues, Catherine Dumartin, Pierre Parneix, Nicole Marty, Jean-Claude Labadie, Jean-Pierre Gachie. (France)
- 63 **Risk Factors of Neuropathy during Rheumatoid Arthritis Treatment with Leflunomide** [141]
Karin Martin, Fabrice Bentaberry, Chantal Dumoulin, Ghada Miremont-Salamé, Joël Dehais, Thierry Schaeberbeke, Françoise Haramburu. (France)
- 64 **Management of Chronic Myeloid Leukemia in France: A Multicentric Cross-Sectional Survey on 538 Patients** [142]
Sophie Tardieu, Catherine Brun-Strang, Patrice Berthaud, Michalet Mauricette, Francois Guilhot, Philippe Rousselot, Roland Sambuc. (France)
- 65 **Prescription Patterns of Leflunomide in Rheumatoid Arthritis: Clinical Trials Compared with Actual Practice** [143]
Karin Martin, Fabrice Bentaberry, Chantal Dumoulin, Joël Dehais, Françoise Haramburu, Thierry Schaeberbeke, Bernard Bégaud. (France, Metropolitan)
- 66 **Evaluation of the UK Clozaril® Patient Monitoring System (CPMS) in the Prevention of Clozaril/Leponex Induced White Blood Cell Count Decline** [144]
Javier Cid Ruzafa, Ana M Rueda de Castro, Branderley Claudio, Chris D Andrews, O'Sullivan P Des. (Spain)

- 67 **Follow-Up of a Pharmacovigilance Study in Psychiatry Involving TDM and Pharmacogenetic Testing [145]**
Eveline E Jaquenoud Siro, Chin B Eap, Pierre Baumann. (Switzerland)
- 68 **French General Practitioners Management of Depression [146]**
François Liard, Thierry Labarthe, Isabelle Gasquet, Sophie Tardieu, Nathalie Joannard, Patrik Blin. (France)
- 69 **Increasing Use of Antipsychotics for Behavioral Indications in Children [147]**
William O Cooper, Gerald B Hickson, D Catherine Fuchs, Patrick G Arbogast, Wayne A Ray. (United States)
- 70 **The Association between Bone Mineral Density and the Use of CNS Active Medications [148]**
Mitsuyo Kinjo, Soko Setoguchi, Sebastian Schneewiess, Daniel H Solomon. (Japan)
- 71 **Cost-Effectiveness of Donepezil Therapy of Alzheimer's Disease in Japan. Results of a 40-year Simulation Study [149]**
Shunya Ikeda, Mia Kobayashi, Naoki Ikegami. (Japan)
- 72 **Comparison of Incidence Rates of Cerebrovascular Accident and Stroke Associated Events for Patients Prescribed Risperidone, Quetiapine and Olanzapine in General Practice in England: Results of a Retrospective Analysis of Prescription-Event Monitoring (PEM) Data [150]**
Deborah Layton, Scott Harris, Andrea Clarke, Lynda V Wilton, Saad AW Shakir. (United Kingdom)
- 73 **SSRI Use in Dutch, German and United States' Youths: Cause for Concern? [151]**
Julie M Zito, Joerg Fegert, Lolkje van den Berg. (United States)
- 74 **Factors Associated with Dependence to Psychoactive Drugs in a Cohort of French Workers [152]**
Bienvenu T Ngoundo, Michel Niezborala, Dominique Briand-Vincens, Pierre Jansou, Evelyne Chastan, Jean-Louis Montastruc, Maryse Lapeyre-Mestre. (France)
- 75 **Price Difference of Antipsychotic Drugs in Asia [153]**
Ataru Igarashi, Tsutani Kiichiro, Takashi Fukuda, Naotaka Shinfuku, Senta Fujii. (Japan)
- 76 **Psychotropic Drugs Use in France: Results from the European Study of Epidemiology of Mental Disorders (ESEMED /MHEDEA 2000) [154]**
Isabelle I Gasquet, Laurence L Negre-Pages, Annie A Fourrier, Viviane V Kovess, Jean Pierre JP Lepine. (France)
- 77 **Psychosocial Factors at Work and Psychoactive Drug Use among Workers: Gender Differences [155]**
Bienvenu T Ngoundo, Michel Niezborala, Jean-Louis Montastruc, Maryse Lapeyre-Mestre. (France)
- 78 **Anxiolytics and Hypnotics Benzodiazepines Deliveries for the Very Elderly in a French Region [156]**
Fanny Romain, Xavier Thirion, Vincent Pradel, Alain Masut, Carine Saillard, Julien Mancini, Christine Coudert, Joëlle Micallef. (France)
- 79 **Weight Change in Ziprasidone and Risperidone Treatment: Randomized Single Blind Multicenter Trial [157]**
Seung-Mi Lee, Yooni Kim, Nam-Kyung Choi, Hwa-Jung Kim, Yong-Sik Kim, Byung-Joo Park. (Korea)
- 80 **Acute Pancreatitis and Serotonin Specific Reuptake Inhibitors - A Signal To Evaluate Further [158]**
Anders Sundström, Sjölin-Forsberg Gunilla, Wiholm Bengt-Erik. (Sweden)
- 81 **Which Factors Influence Prescription to Depressed Patients? Comparison between Community Psychiatrists and General Practitioners [159]**
Sophie Tardieu, Isabelle Gasquet, Alain Bottero, Alain Gerard, Thierry Labarthe, Francois Liard, Patrick Blin, Michael Bohbot, Thierry Marquet, Sylvia Goni. (France)
- 82 **Cost-Effectiveness Analysis of Atypical Antipsychotics in Schizophrenia [160]**
Dan Cooper, Jocelyne Moisan, Michel Gaudet, Belkacem Abdous, Jean-Pierre Gregoire. (Canada)
- 83 **Characterizations of Benzodiazepine Prescriptions in Veteran Patients [161]**
John A Hermos, Melissa M Young, Margaret R Stedman, David R Gagnon, Louis D Fiore. (United States)
- 84 **Oral Anti-Spastic Drugs in Non-Progressive Neurological Diseases: A Systematic Review [162]**
Eva Montane, Antoni Vallano, Joan-Ramon Laporte. (Spain)
- 85 **Sudden Unexpected Death (SUDEP) in Children and Adolescents with Epilepsy [163]**
Yingfen Hsia, Corinne S de Vries. (United Kingdom)
- 86 **Patterns of Psychotropic Drug Use in Young Children (Less Than 6 Years): Data from the Social Security Database of Aquitaine, South-Western France [164]**
Laurie Lévy, Annie Fourrier-Réglat, Philippe Latry, Nathalie Lechevallier, Corinne Martin-Guehl. (France)
- 87 **Do Depressed Patients Who Are Given Guideline Concordant Pharmacotherapy Use More or Less Health Services? [165]**
Maida J Sewitch, Regis Blais, Elham Rahme, Sophie Galarneau, Brian Bexton. (Canada)
- 88 **Determinants of Guideline Concordant Pharmacotherapy in Adolescents Diagnosed with Depressive Disorders [166]**
Maida J Sewitch, Regis Blais, Elham Rahme, Brian Bexton, Sophie Galarneau. (Canada)
- 89 **Supportive Behaviour in Working Environment: Patterns of Drug Use in a Sample of 2106 Workers in Southwestern France [167]**
Maryse Lapeyre-Mestre, Bienvenu T Ngoundo, Michel Niezborala, Dominique Briand-Vincens, Pierre Jansou, Evelyne Chastan, Jean-Louis Montastruc. (France)
- 90 **A Long Term Follow-Up Study of Patients Treated by Buprenorphine as a Maintenance Treatment for Opiate Dependence: A Study Using Data from the French Insurance System Prescription Database [168]**
Maryse Lapeyre-Mestre, Mireille Gony, Anne-Marie Navel, Jacques Bez, Jean-Louis Montastruc. (France)
- 91 **Is Rational the Present Polypharmacy of Psychiatric Patients? [169]**
Carlos De Las Cuevas, Emilio J Sanz. (Spain)
- 92 **The Pattern of Antipsychotic Drugs Coprescribing in Psychiatric Hospital in Belgrade [170]**
Nevena V Divac, Ranka Samardzic, Miroslava Jasovic-Gasic, Milica P Bajcetic. (Yugoslavia)
- 93 **Development of a National System for Drug of Abuse Monitoring: Results of the Osiap Survey (Ordonnances Suspectes Indicateur d'Abus et de Pharmacodependance) [171]**
Maryse Lapeyre-Mestre, Isabelle Lacroix, Francoise Haramburu, Valerie Auclair, Michel Mallaret, Nathalie Bernard, Jocelyne Arditti, Catherine Armand-Malaplatte, Caroline Vigneau, Martine Assouly, Marie-Christine Perault. (France)
- 94 **Recruitment of Parents and Doctors of Stimulant-Using Children Via Community Pharmacies [172]**
Adrienne Faber, Luuk J Kalverdiijk, Lolkje TW de Jong-van den Berg, Ruud B Minderaa, Hilde Tobi. (Netherlands)
- 95 **The Use of Stimulants and Co-Prescribed Psychotropic Medication among Children in the Netherlands from 2000 to 2002 [173]**
Adrienne Faber, Hilde Tobi, Lolkje TW de Jong - van den Berg. (Netherlands)
- 96 **Sertindole Reduces Health Care Resource Consumption in Schizophrenia: Results of a Mirror Study [174]**
Christophe Sapin, Jean-Michel Azorin, Agathe Le Lay, Karina Hansen. (France)
- 97 **Benzodiazepine Prescribing and Patient Age [175]**
Therese E Kairuz, Ilse Truter. (South Africa)
- 98 **Prescribing of Anti-Migraine Agents in a South African Patient Setting [176]**
Ilse Truter. (South Africa)
- 99 **Methylphenidate: Prescribing Patterns in South Africa [177]**
Ilse Truter. (South Africa)



- 100** **Patterns and Frequency of Atypical Antipsychotic Drugs (Apos) Prescribing in French Psychiatric Medical Centers [178]**
Thierno Diatta, Sylvie Blazejewski, Ariane Quesnot, Severine Lignot, Arnaud Portier, Myriam Bouhassira, Annie Fourrier. (France)
- 101** **Parents' Attitudes and Psychopharmacological Treatment of Children [179]**
Hilde Tobi, Luuk J Kalverdiijk, Hillegonde Nusse, Ruud B Minderaa. (Netherlands)
- 102** **Are Methylphenidate Users Insured under a Private Drug Plan Similar to Those Users Insured under a Public Drug Plan? [180]**
Melanie St-Onge, Jocelyne Moisan, Andre Simpson, Suzanne Gingras. (Canada)
- 103** **Impact of Substance Use on the Seriousness of Parasuicide [181]**
Marie Tournier, Mathieu Molimard, Abdelilah Abouelfath, Audrey Cougnard, Annie Fourrier, H el ene Verdoux. (France, Metropolitan)
- 104** **Antiepileptic Drug Utilization in the General Population in Italy [182]**
Nicola Vanacore, Giuseppe Traversa, Roberto Da Cas, Mariangela Rossi. (Italy)
- 105** **How Should Antidepressant Drug Effects Be Reported? [183]**
Ivar Aursnes. (Norway)
- 106** **Are Children and Youths with Attention-Deficit/Hyperactivity Disorder Accident Prone? [184]**
Elke Scharnetzky, Walter Schill, Gerd Glaeske, Katrin Janhsen. (Germany)
- 107** **Safety of Acetylcholinesterase Inhibitors in Alzheimer's Disease. Experience from the Italian Cronos Study [185]**
Marina Maggini, Roberto Raschetti, Giacomina Carla Sorrentino, Bruno Caffari, Nicola Vanacore. (Italy)
- 108** **Incidence of Fractures among Epilepsy Patients: A Cohort Study in the General Practice Research Database [186]**
Patrick C Souverein, David J Webb, Hans L Petri, Tjeerd P van Staa, Toine CG Egberts. (Netherlands)
- 109** **Polypsychopharmacy in Schizophrenia In-Patients [187]**
Shu-yu Yang, Mian-Yoon Chong, Yea-Huei Kao Yang. (Taiwan)
- 110** **Drug Prescribing by Dutch Child and Adolescent Psychiatrists [188]**
Jacqueline G Hugtenburg, Eibert R Heerdink, Antoine CG Egberts. (Netherlands)
- 111** **The European Schizophrenia Cohort (EuroSC): Description and Preliminary Findings [189]**
Paul Bebbington, Matthias C Angermeyer, Jean-Michel Azorin, Traolach Brugha, Mondher Toumi. (France)
- 112** **Characteristics of Spontaneous Reporting Concerning Drug Abuse or Dependence: Analysis of Data Collected Via the NotS System by a French Ceip [190]**
Maryline Desplas, Isabelle Lacroix, Christine Damase-Michel, Jean-Louis Montastruc, Maryse Lapeyre-Mestre. (France)
- 113** **SCoP Study (Sertindole Cohort: Prospective Study): Sertindole Versus Risperidone Outcome Study [191]**
Patrice Verpillat, Aur elia Mittoux, Peter Schuck, Frank Kuhn, Lowijs Perquin, Jozef Peuskens. (France)
- 114** **Meta-Analysis of Remission Rates of Escitalopram in the Treatment of Major Depressive Disorder in Primary Care [192]**
Thomas R Einarson. (Canada)
- 115** **Cholinesterase Inhibitors and Liver Disorders: Safety Profile Analysis in the FDA SRS/AERS Database [193]**
Javier Cid Ruzafa, Carles Blanch, Ana M Rueda de Castro, Barbara A Warner. (Spain)
- 116** **The Feasibility of GP P-IIIa Antagonists Use in the Treatment of Patients with Acute Coronary Syndrome in the Department of Internal Medicine [194]**
Zaher S Azzam, Elias Sa'ad, Amal Jabarin, Oron Eilam, Norberto Krivoy. (Israel)
- 117** **Evaluation of African Traditional Management of Hypertension in the Nelson Mandela Metropole, South Africa [195]**
Mbali Z Luvuno, Maryna Van De Venter, Ilse Truter, Mea Van Huyssteen. (South Africa)
- 118** **Therapeutic Traditions and Compliance to Guidelines When Prescribing HMG-CoA Reductase Inhibitors [196]**
Henrik Ohlsson, Juan Merlo, Ulf Lindblad, Thor Lithman, Dennis Noreen, Bodil Ericsson. (Sweden)
- 119** **Declined Presentation**
- 120** **Evidence for Inequalities in the Management of Coronary Heart Disease in Scotland [198]**
Colin R Simpson, Philip C Hannaford, David JP Williams. (United Kingdom)
- 121** **RCT Findings, Promotional Expenditures, and Prescribing Behavior: The Case of Doxazosin [199]**
Giuseppe Traversa, Roberto Da Cas, Clara Bianchi, Carlo Romagnoli. (Italy)
- 122** **A Multilevel Model for Statin Discontinuation and Switching Using a Large Prescribing Database [200]**
Nicola Fitz-Simon, Kathleen Bennett, John Feely. (Ireland)
- 123** **Changes in Prevalence of and Prescribing for Ischaemic Heart Disease in Ireland 1990-2002 [201]**
Kathleen Bennett, Howard Johnson, Pat Dack, John Feely. (Ireland)
- 124** **Persistence with Different Formulations of the Antihypertensive Drug Nifedipine [202]**
Nancy S Breekveldt-Postma, Ron MC Herings. (Netherlands)
- 125** **Assessing the Prevalence and Treatment of Coexisting Hypertension and Hypercholesterolaemia: A Comparison of Two Sampling Methods [203]**
Bryan Williams, Koo Wilson, Loretto Lacey, Steve Lister, Nick Marchant, Charles Phillips. (United Kingdom)
- 126** **Treatment of High-Risk Hypertensive Patients in the United Kingdom: 1997 to 2001 [204]**
Thomas M MacDonald, Steve V Morant, Christine L Baker, Essy Mozaffari. (United Kingdom)
- 127** **Use of Platelet Aggregation Inhibitors after Ischemic Vascular Events in the Netherlands [205]**
Wim G Goettsch, Marco JD Tangelder, Ron MC Herings. (Netherlands)
- 128** **Use of Antihypertensive Drugs and Control of Hypertension in Oslo. The Oslo Health Study 2000-2001 [206]**
Serena Tonstad, Kari Furu, Elin Olaus Rosvold, Svetlana Skurtveit. (Norway)
- 129** **Can Tight Blood Pressure Control towards Ideal Levels Be Cost-Effective? [207]**
Louis Coupal, Steven Grover, Vivian Ho, Fr ed eric Lavoie, Carl Brewer, Hanna Zowall. (Canada)
- 130** **Why Does Consumption of Lipid-Lowering Drugs Vary between Regions in Norway? [208]**
Ingeborg H Bartnes, Anne Elise Eggen, Kari Furu, Inger Njolstad, Svetlana Skurtveit. (Norway)
- 131** **Real-Life Statin Prescription Patterns in South-West France [209]**
Karin Martin, Bernard B egaud, Abdelilah Abouelfath, Philippe Latry, Nicholas Moore. (France, Metropolitan)
- 132** **Impact of an Outpatient Physician Education Program on Beta-Blocker Usage for Secondary Prevention of Myocardial Infarction [210]**
Irene H Zuckerman, Sheila R Weiss, Diane McNally, Barbara Layne, C Daniel Mullins, Junling Wang. (United States)
- 133** **Developing a Method To Identify Prescribing Profiles of Antihypertensive Drugs in General Practice [211]**
Claudio Voci, Giulia Sangiorgi Cellini, Chiara Silvani, Elisabetta Poluzzi, Antonio Vargiu, Alberto Vaccheri, Nicola Montanaro, Paolo Mosna. (Italy)
- 134** **The Adherence to Antihypertensive Treatments: An Italian Survey by Using Prescription Databases [212]**
Elisabetta Poluzzi, Chiara Silvani, Giulia Sangiorgi Cellini, Claudio Voci, Petar Strahinja, Alberto Vaccheri, Nicola Montanaro. (Italy)



- 135 Statin Compliance among Newly Treated Dyslipidemic Patients in Oman [213]**
Bruno Louis, Kassim A Al Riyamy, Ibrahim S Al Zakwani. (Oman)
- 136 Insertion/Deletion Polymorphism of the Ace Gene and Antihypertensive Response to Ace-Inhibitors [214]**
Hedi Schelleman, Olaf H Klungel, Cornelia M van Duijn, Jacqueline CM Witteman, Albert Hofman, Anthonius de Boer, Bruno HCh Stricker. (Netherlands)
- 137 Availability of Pharmacogenomics-Based Prescribing Information in Drug Package Inserts for Currently Approved Drugs [215]**
Issam Zineh, Tobias Gerhard, Christina L Aquilante, Amber L Beitelshes, B Nhi Beasley, Abraham G Hartzema. (United States)
- 138 Interactions between Genetic Polymorphisms and Antihypertensive Drugs in the Treatment of Hypertension [216]**
Karin JA Lievers, Anthonius de Boer, Bruno HCh Stricker, Diane MA de Wijer, Abraham A Kroon, Peter W de Leeuw, Cornelia M van Duijn, Monique WM Verschuren, Olaf H Klungel. (Netherlands)
- 139 Defined Daily Dose (DDD) Changes Are Associated with Drug Metabolism through CYP450 [217]**
Pieter Stolk, Eibert R Heerdink, John Urquhart, Hubert GM Leufkens. (Netherlands)
- 140 Worldwide Differences in Spontaneous Adverse Event Reporting Rates [218]**
Jasmanda H Wu, Wanju S Dai, Paul R Lagarenne, Rhonda L Bohn. (United States)
- 141 Comparison of Different Methods for Signal Detection in the Drug-Safety Database of a Pharmaceutical Company [219]**
Markus Follmann, Alexander Michel, Christina Geyer. (Germany)
- 142 Adverse Drug Reactions and Other Drug Related Problems as a Cause of Hospital Admission: A Retrospective Study [220]**
Ilma Bertulyte, Jolanta Gulbinovic. (Lithuania)
- 143 Safety Profile of Desloratadine as Used in General Practice in England: Results of a Prescription-Event Monitoring Study [221]**
Deborah Layton, Lynda V Wilton, Saad AW Shakir. (United Kingdom)
- 144 Safety Profile of Levocetirizine as Used in General Practice in England: Results of a Prescription-Event Monitoring Study [222]**
Deborah Layton, Lynda V Wilton, Saad AW Shakir. (United Kingdom)
- 145 Analysis of Design Quality and Potential Bias in Reports Acceptance of Trials on Antihypertensive Therapy Presented at the 12 and 13-Th Meetings of the European Society of Hypertension [223]**
Maksim N Mily, Sergey A Golubev. (Sweden)
- 146 Predictors of Completed Academic Detailing Encounters with Primary Care Physicians [224]**
Jennifer M Polinski, M Alan Brookhart, Jerry Avorn, Michele Burgener, Danielle Cabral, Andrea Licari, Daniel H Solomon. (United States)
- 147 The Impact of Prescription Audit on Prescribing Skills of Medical Students [225]**
Ahmet Akici, M Zafer Gören, Cenk Aypak, Berna Terzioglu, Sule Oktay. (Turkey)
- 148 Adverse Event Reporting in Paediatrics [226]**
Mireya R Schmickler. (Germany)
- 149 The Importance of the Drug Information Center as an Instrument of Pharmacovigilance [227]**
Emilia V Silva, Janeth OS Naves, Lia LC Castro, Camila Zakir, Carlos CF Vidotti, Mariana HM Cunha, Hoefler Rogerio. (Brazil)
- 150 Quality Management in Pharmacovigilance: Effects on Quality of Reports [228]**
Bina Kramhoft Schack. (Denmark)
- 151 Identification of Ophthalmic Adverse Events with Particular Reference to Special Populations: Can We Learn from Our Experience? [229]**
Rhonda L Bohn, Wanju S Dai. (United States)
- 152 Day of Hospitalization and Inpatient HIV Medication Errors [230]**
C Jessica Dine, Russell Localio, Mark Cary, Janet Hines, Amelia Graziani, Robert Gross. (United States)
- 153 Clinical Trials Are Not Reported Satisfactory to the Authorities [231]**
Steinar Madsen, Bente Fjeld, Linda Sandaker, Harald Lislevand, Aasmund Reikvam. (Norway)
- 154 Pharmacovigilance – National Reporting System of Monitoring Adverse Reactions of Medicinal Products, Via E-Mail, in Brazil [232]**
Elenice Lacerda, Murilo F Dias, Nair R Souza, Patricia M Figueiredo, Juliana B Barra. (Brazil)
- 155 Serious Side-Effects of Bupropion. Who Is at Risk among 524 000 Exposed Patients? [233]**
Marie-Noelle Beyens, Silvy Laporte, Michel Ollagnier. (France)
- 156 Agranulocytosis and Calcium Dobesilate: Signal or Not Signal? [234]**
Karin Martin, Bernard Bégau. (France, Metropolitan)
- 157 Adverse Drug Reaction Profiles for Fluoxetine, Paroxetine and Amitriptyline Using Data Recorded by General Practitioners in the United Kingdom (UK) [235]**
Sarah Davis, Stephan Rietbrock, Carlos Martinez. (United Kingdom)
- 158 Agreement of Expert Judgment in Assessment of Causality of Adverse Drug Reactions [236]**
Yannick Arimone, Bernard Begaud, Ghada Miremont-Salame, Françoise Haramburu, Annie Fourrier-Reglat. (France)
- 159 Reports of Cardiovascular Events for Sibutramine as Used in General Practice in England: Results of a Prescription-Event Monitoring Study [237]**
Hilary M Pearce, Lynda V Wilton, Saad AW Shakir. (United Kingdom)
- 160 Gefitinib-Induced Interstitial Pneumonia in Japan. – Problems in the Approval Process, Pharmacovigilance and Regulatory Decision-Making [238]**
Harue Tada, Naomi Yokoyama, Masatsugu Nakagawa, Shigeyuki Matsui, Satoshi Teramukai, Masanori Fukushima. (Japan)
- 161 Adverse Drug Reactions in an Intensive Care Unit [239]**
Luis E Salazar Domínguez, Juan de Dios Hernández Beguiristain, Jorge R Pérez Cruz, Jorge Diaz Mayo. (Cuba)
- 162 Use of Anti-Inflammatory Therapy and Asthma Mortality in Portugal from 1991-2001 [240]**
Magda N Melo, Zilda Mendes, Paula Martins, Samy Suissa. (Portugal)
- 163 Pharmacovigilance and Reporting Therapeutic Ineffectiveness as an Adverse Drug Reaction in Brazil [241]**
Nair R Souza, Murilo F Dias, Elenice Lacerda, Patricia M Figueiredo, Juliana B Barra, Esther S Silva, Dayana A Silva. (Brazil)
- 164 Stavudine Usage and the Incidence of Peripheral Neuropathy in HIV/AIDS Patients [242]**
Gordana J Dragovic, Djordje Lj Jevtovic. (Yugoslavia)

END - Session A



- 1 **A Randomised, Controlled Trial of Antipsychotic Drug Withdrawal in Dementia [296]**
Sabine Ruths, Jorund Straand, Harald A Nygaard. (Norway)
- 2 **Impact of the New Guidelines from the French Medicine Agency (Afssaps) on Low Molecular Weight Heparin Use in a French University Hospital [297]**
Sophie Leclerc, Haleh Bagheri, Kamran Samii, Jean-Louis Montastruc, Maryse Lapeyre-Mestre. (France)
- 3 **Targeted Academic Detailing To Reduce Suboptimal Antimicrobial Use in a Teaching Hospital [298]**
Charles A Morris, Fischer Michael, Jerry Avorn. (United States)
- 4 **Impact of a Two Phase Intervention on Antimicrobial Prescribing Behavior [299]**
Peter GM Mol, Prashant V NannanPanday, Jaap E Wieringa, Rijk OB Gans, John E Degener, Marian Laseur, Flora M Haaijer-Ruskamp. (Netherlands)
- 5 **Impact of Generic Substitution on Ambulatory Drug Costs in Finland [300]**
Tinna J Voipio, Pirkko K Paakkari, Erkki S Palva, Esko J Nuotto. (Finland)
- 6 **Mortality Increase after Coprescribing Cisapride and Contraindicated Drugs [301]**
Nam-Kyong Choi, Yooni Kim, Seung-Mi Lee, Hwa-Jung Kim, Byung-Joo Park. (Korea)
- 7 **Challenges and Lessons in Pharmacoepidemiology: Analyzing Longitudinal Data [302]**
Caro Badcock, Lisa G Pont, Stephen J Kerr, Judith M Mackson, John Mandryk, Sonia Wutzke, Lynn Weekes. (Australia)
- 8 **Dosage of Anti-Hypertensive Drugs and Stroke Incidence among Hypertensives [303]**
Fausto Marchetta, Mirko Di Martino, Giorgia Valpiani, Rossella Miglio, Leona Bassein, Alessandra Sturani, Ezio Degli Esposti. (Italy)
- 9 **Prescription of Homeopathics and Herbal Medicines before and during Pregnancy [304]**
Veronika Egen-Lappe, Joerg Hasford, Martina Koethemann. (Germany)
- 10 **Persistence with Antihypertensive Therapy in Newly Diagnosed Patients - A Population-Based Study [305]**
Chantal Bourgault, Martin Sénécal, Marc Brisson, Michael Marentette, Grégoire Jean-Pierre. (Canada)
- 11 **Factors Associated with the Initiation and Discontinuation of Secondary Stroke Prevention Agents in US Nursing Homes [306]**
Carmel M Hughes, Kate L Lapane. (United States)
- 12 **Is Hospitalisation a Determinant of Initiation and Long-Term Use of Benzodiazepines? [307]**
Rutger Stuffken, Kris LL Movig, Toine CG Egberts. (Netherlands)
- 13 **Drug Utilization Review (DUR) for the Treatment of Asthma [308]**
Joëlle Mimeault, Diane Blais, Members of the Conseil du médicament. (Canada)
- 14 **The Association between Area-Based Deprivation and Prescribing Patterns in Ireland [309]**
Cara Usher, Kathleen Bennett, John Feely. (Ireland)
- 15 **Does the Organization of Maternity Wards Affect Postnatal Drug Use? [310]**
Hedvig Nordeng, Britt-Ingjerd Nesheim, Anne Eskild, Ivar Aursnes. (Norway)
- 16 **Patient Persistency with Topical Ocular Hypotensive Therapy [311]**
Beth L Nordstrom, David S Friedman, Essy Mozaffari, Reinee E Sheffield, Harry A Quigley, Alexander M Walker. (United States)
- 17 **Quinolone Utilisation in Children and Adolescents [312]**
Ahmet Akici, Corinne S de Vries. (Turkey)
- 18 **Use of Herbal Products during Pregnancy [313]**
Carol Louik, Margaret A Honein, Martha M Werler, Allen A Mitchell. (United States)
- 19 **Methodological Issues in Determining Daily Hormonal Contraceptive Exposure on the General Practice Research Database [314]**
Julia M Snowball, Richard DT Farmer. (United Kingdom)
- 20 **Does the Early Adopter of Drugs Exist? A Population Based Study of General Practitioners' Prescribing of New Drugs [315]**
Torben Dybdahl, Morten Andersen, Jens Sondergaard, Jakob Kragstrup, Ivar Sonbo Kristiansen. (Denmark)
- 21 **Therapeutic Traditions and Compliance with Local Therapeutic Guidelines on Lipid Lowering Drugs - A Multilevel Analysis in the Skarborg Primary Healthcare Database (SPHD) [316]**
Per Hjerpe, Juan Merlo, Ulf Lindblad, Sven Fornwall. (Sweden)
- 22 **Analysing Drug Overuse in a Prescription Database: Estimation Method Matters [317]**
Morten Andersen, Jens Sondergaard. (Denmark)
- 23 **Drug Interactions in Primary Care: Impact of a New Algorithm on Risk Determination [318]**
Verena Bergk, Christiane Gasse, Dietrich Rothenbacher, Michael Loew, Hermann Brenner, Walter E Haefeli. (Germany)
- 24 **Pattern of Use of NSAIDs in the Italian General Population: A Questionnaire-Based Study [319]**
Domenico Motola, Elisabetta Poluzzi, Chiara Silvani, Claudio Voci, Fabrizio De Ponti, Alberto Vaccheri, Nicola Montanaro. (Italy)
- 25 **Impact of Potentially Inappropriate Drug Use on Mortality among Nursing Home Residents [320]**
Brian J Quilliam, Muhammed S Alsultan, E Paul Larrat, Kate L Lapane. (United States)
- 26 **Non-Adherence to Evidence-Based Guidelines in the Initial Treatment of Hypertension [321]**
Michael A Fischer, Raisa Levin, Jerry Avorn. (United States)
- 27 **Doctor-Shopping for Buprenorphine in a French Region: Method for Assement and Trends from 2000 to 2002 [322]**
Vincent Pradel, Xavier Thirion, Christine Coudert, Alain Masut, Joëlle Micallef. (France)
- 28 **Socio-Demographic Risk Factors for Polymedication in a French Community-Dwelling Elderly Population: Results from the Three-City Study [323]**
Nathalie Lechevallier-Michel, Annie Fourrier-Reglat, Jean-Francois Dartigues, Annick Alperovitch. (France)
- 29 **Socio-Economic Inequalities in the Use of Antidepressants? [324]**
Dorte Gilså Hansen, Jens Soendergaard, Werner Vach, Lars F Gram, Jens-Ulrik Rosholm, Preben B Mortensen, Jakob Kragstrup. (Denmark)
- 30 **Trends in Antibiotic Consumption in Ambulatory Care in Europe [325]**
Monique M Elseviers, Robert H Vander Stichele, Matus Ferech, Herman Goossens, ESAC Management Team. (Belgium)
- 31 **Appropriateness of Clopidogrel Prescribing in a Primary Care Setting [326]**
Janice Watt, Richard Lowrie, Keith Beard, Anne Lee. (United Kingdom)
- 32 **Antidiabetic Prescribing Patterns in Portuguese Type 2 Diabetics - Collecting Valuable Information To Estimate Disease Prevalence [327]**
Filipa Duarte-Ramos, Jose Cabrita. (Portugal)
- 33 **Prescription Patterns of Oral Anticoagulants and Knowledge of Outpatients about Their Treatment: The Impact of an Information Campaign in France [328]**
Association Francaise des Centres, Regionaux de Pharmacovilance. (France)
- 34 **A First Year of Generic Substitution; How Do Doctors, Patients and Pharmacy Staff Act? Experiences from Region Västra Götaland, Sweden [329]**
Karolina Andersson, Anders Carlsten, Knut Lönnroth, Max Petzold, Christian Sonesson. (Sweden)
- 35 **Antipsychotic Treatment Patterns among French Schizophrenic Outpatients: The Epi Survey [330]**
Patrick Blin, Jean-Pierre Olié, Philippe Cialdella, Alain Gérard, François PetitJean, Daniel Sechter, Linda Hanssens, Jérémie Westerloppe. (France)

- 36 **Calcium and Vitamin D Supplement Use in Long-Term Care Residents [331]**
Stephen P Motsko. (United States)
- 37 **Deliveries of Anxiolytics, Hypnotics and Antidepressants to Adolescents in a French Region in 2002 [332]**
Julien Mancini, Xavier Thirion, Alain Masut, Carine Saillard, Vincent Pradel, Fanny Romain, Christine Coudert, Joëlle Micallef. (France)
- 38 **Can Local Consensus Process and Peer Review Improve Treatment for Chronic Cardiovascular Problems? [333]**
Willeke Kasje, Petra Denig, Pieter de Graeff, Flora M Haaijer-Ruskamp. (Netherlands)
- 39 **Social and Behavioral Characteristics of Aspirin Users: Japan Nurses' Health Study [334]**
Kota Katanoda, Yasuhiro Matsumura, Hirofumi Takagi, Jung Su Lee, Toshiharu Fujita, Kunihiko Hayashi. (Japan)
- 40 **Drugs Used in Euthanasia and Physician Assisted Suicide in Four European Countries [335]**
Johan Bilsen, Agnes van der Heide, Freddy Mortier, Michael Norup, Eugenio Paci, Gerrit van der Wal, Rurik Lofmark, Georg Bosshard, and on behalf of the Eureld Consortium. (Belgium)
- 41 **The Impact of an Unrestricted Access Policy for Atypical Antipsychotic Medications in Newfoundland and Labrador [336]**
Daria J O'Reilly, Patrick S Parfrey. (Canada)
- 42 **What Is My Indicator Telling Me?: Dilemmas in Interpreting Prescribing Indicators [337]**
Lisa G Pont, Jacoba P Greving, Heidrun Sturm, Flora Haaijer-Ruskamp. (Australia)
- 43 **Clinical Correlates and Drug Treatments of a Nursing Home Population with a Recent Stroke and Comorbid Depression [338]**
Brian J Quilliam, Matthew M Lacroix, Kate L Lapane. (United States)
- 44 **Surgery Versus Radiation: Is There a Difference in Prostate Cancer-Specific Mortality? [339]**
Michael D Taylor. (United States)
- 45 **The Effect of Hypertension and Hypercholesterolemia Screening with Subsequent Intervention Letter on the Use of Blood Pressure and Lipid Lowering Drugs [340]**
Jarir Aththobari, Taco BM Monster, Paul E de Jong, Lolkje TW de Jong van den Berg. (Netherlands)
- 46 **Multivitamin Use among Children Aged 2-11 Years [341]**
Judith P Kelly, David W Kaufman, Lynn Rosenberg, Allen Mitchell. (United States)
- 47 **Sleeping Pill Use and Users' Characteristics: Japan Nurses' Health Study [342]**
Shuku Fujimaki, Toshiharu Fujita, Shosuke Suzuki, Hideki Mizunuma, Takeshi Aso, Alexander Walker, Kunihiko Hayashi. (United States)
- 48 **Contraindicated Drug Prescriptions to Children [343]**
Lamia Bensouda, Annie Pierre Jonville-Bera, Nathalie Sarraf, Francoise Doisy, Elisabeth Autret-Leca, Jacques Pivette. (France)
- 49 **Potentially Inappropriate Medication Use by Patients 70 Years and Older [344]**
Marie-Laure Laroche, Yves Nouaille, Monique Amaniou, Jean-Pierre Charmes, Louis Merle. (France)
- 50 **Detection and Treatment of Depression in General Practice [345]**
Ahmad Al-windi. (Sweden)
- 51 **Evidence Based Treatment Training Intervention for Reducing Medication Errors in Primary Health Centres [346]**
Erna Kristin, Iwan Dwiprahasto, Jarir At Thobari. (Indonesia)
- 52 **Impact of the Withdrawal of Cerivastatin on the Prescribing Patterns of the Other Statins [347]**
Therese M Rafferty, Briegen G Girvin, Michael R Stevenson, Dennis G Johnston. (United Kingdom)
- 53 **The Nordic Method for Quality Improvement in General Practice: A Randomised Controlled Study [348]**
Jens Sondergaard, Dorte Gilså Hansen, Peter Aarslev, Henrik Stovring, Anders Peter Munk. (Denmark)
- 54 **Utilization of Psychotropic Drugs in Banja Luka Region (North-West Bosnia): 8-year Follow-Up [349]**
Lana Nezic, Ranko Skrbic, Sveltana Stoisavljevic Satara, Natasa Stojakovic, Milenka Vucen. (Bosnia and Herzegovina)
- 55 **Misuse of Clonazepam in France: Prescription Database Analysis [350]**
Elisabeth Frauger, Xavier Thirion, Charles Chanu, François Natali, Chantal Gagnon, Carine Saillard, Vincent Pradel, Patrick Reggio, Joëlle Micallef. (France)
- 56 **Simple Economic Model of HIV/Aids Prevention and Treatment in Private Sector Settings for Developing Countries [351]**
Douglas E Ball, Klara Tisocki. (Kuwait)
- 57 **Patterns of Risperidone Prescriptions: A Utilization Study in Southwest France [352]**
Karin Martin, Bernard Bégau, Hélène Verdoux, Nathalie Lechevallier, Philippe Latry, Nicholas Moore. (France, Metropolitan)
- 58 **"Ten Wise Tips about Medications" - A Computerised Tool for Self Directed Monitoring of Adherence of Public Health Issued Guidelines in the Health Care System in Stockholm [353]**
Per Gæransson, Sten Ronge, Æke Karlsson, Ann-Sofie Mangs, Bjørn Wettermark, Ulf Bergman, Lars L Gustafsson. (Sweden)
- 59 **Antibiotics: Evolution of Prescription's Behaviour in France [354]**
Julie Biga, Florence Taboulet, Maryse Lapeyre-Mestre, Robert Bourrel, Vincent Sciortino, Alain Grand, Jean-Louis Montastruc. (France)
- 60 **Evaluation of Drug Formulary System Suitability for Improving Pharmaceuticals Supply and Utilization in Hospital Setting in Belarus [355]**
Maksim N Mily, Irina M Samsonova, Vladimir Y Lugovoy. (Sweden)
- 61 **Extended and Targeted Drug Information at Pharmacies: Attitudes to the Concept and Barriers To Impact [356]**
Jens Sondergaard, Annette Foged, Morten Andersen. (Denmark)
- 62 **Improved Adherence to Guidelines by Outpatient Prescription Feedback to Hospital Based Specialists - A Controlled Intervention Study [357]**
Bjorn Wettermark, Kjell Haglund, Lars L Gustafsson, Peter Persson, Ulf Bergman. (Sweden)
- 63 **Do Physicians Agree with Generic Substitution? [358]**
Karolina Andersson, Tove Jörgensen, Anders Carlsten. (Sweden)
- 64 **Regional and Social Variation in Iron Prescribing to Pregnant Women [359]**
Barbara Rebhan, Christine Strunz-Lehner, Veronika Egen-Lappe, Joerg Hasford, Katrin Janhsen, Gerd Glaeske. (Germany)
- 65 **Potential Drug Interactions Deriving from the Use of Over-the-Counter (OTC) Medicines [360]**
Maria Jesus Aragon-Martinez, Maria Luisa Martin-Calvo, Ramona Mateos-Campos. (Spain)
- 66 **Evaluation of Drug Misuse in Gastrointestinal Bleedings Collected in the University Hospital of Dijon (France) [361]**
Catherine Sgro, Francois Clinard, Cyril Hatem, Salwa Layka, Anne Disson-Dautriche, Olivier Coatmeur, Patrick Hillon. (France)
- 67 **Characteristics of Physicians Who Prescribed and Did Not Prescribe LOTRONEX® (ALOSETRON HCL) after Its Reintroduction [362]**
Gregg S Wilkinson, Alexander M Walker, Heather Norman, Suzanne F Cook. (United States)
- 68 **The Impact of Region and Social Status on Drug Prescribing during Pregnancy [363]**
Christine Strunz-Lehner, Veronika Egen-Lappe, Joerg Hasford, Katrin Janhsen, Gerd Glaeske. (Germany)
- 69 **The Utilization Pattern of Carbamazepine of Three Medical Centers in Taiwan [364]**
Yao-Teh You, Chiung-Fang Tai, Churn-Shiouh Gau. (Taiwan)
- 70 **Prescribing Patterns of Common Antibiotics Used in a Neonatal Intensive Care Unit (NICU) [365]**
Ching-Lan Cheng, Yea-Huei Kao Yang, Shu-Hua Tai, Yuh-Jyh Lin, Chyi-Her Lin. (Taiwan)
- 71 **Content of the Medicine Cupboards of a Sample of South African Households [366]**
Ilse Truter, Suzette Bignonault. (South Africa)



- 72 **Antidepressant Dispensings for Post-Stroke Veterans [367]**
L Douglas Ried, Michael J Tueth, Diane McMullen. (United States)
- 73 **Regulatory Action and Trends in Prescribing of Epoetins and Spontaneous Suspected ADR Reports of Pure Red Cell Aplasia (PRCA) in the United Kingdom (UK) [368]**
Emma L Heeley, William N Richardson. (United Kingdom)
- 74 **The Potential Drug-Drug Interactions in an Ambulatory Prescription Data in Taiwan [369]**
Mei-shu Lin, Nen-Chung Chang, Yea-huei Kao Yang, Yen-Hui Chen. (Taiwan)
- 75 **Increased Prescribing of Anti-Osteoporotic Therapy Following Exposure to Inhaled Steroids [370]**
David Williams, Kathleen Bennett, John Feely. (United Kingdom)
- 76 **Subdosing of Antibiotics in Children with Cardiovascular Disease [371]**
Milica Bajcetic, Nevena Divac, Slavko Simeunovic, Ranka Samardzic. (Yugoslavia)
- 77 **Deaths In Young Women Using Flutamide in Brazil [372]**
Patricia M de Figueiredo, Esther S da Silva, Murilo F Dias, Nair R de Souza, Elenice Lacerda, Danila AV Barca. (Brazil)
- 78 **Monitoring the Effects of New Evidence on Menopausal Hormone Therapy Prescription Patterns [373]**
Bernhilde Deitermann, Katrin Janhsen, Petra Kolip, Gerd Glaeske. (Germany)
- 79 **Drug Use Evaluation of Colony Stimulating Factors in Sultan Qaboos University Hospital in Oman [374]**
Badria A Al-Zadjali, Mansour Al-Moundhri, Yasser A Wali, Kassim A Al-Riyami. (Oman)
- 80 **Appropriate Prescribing for Persons at High Risk of GI Complications: Current Findings from General Practice [375]**
Colleen J Metge, Malcolm Doupe, Alan Katz, Brent Kvern, Lori-Jean Manness, Glen Thomson, Marina Yogendran. (Canada)
- 81 **Quantitative Analysis of the Reimbursement Procedure in Belgium [376]**
Alain G Dupont, Philippe B Van Wilder, Jean Paul Degaute, Hugo Robays, Francis Aricx, Gert A Verpooten. (Belgium)
- 82 **Early Discontinuation of Antidepressants in General Practice: Association with Patient and Prescriber Characteristics [377]**
Dorte Gilså Hansen, Werner Vach, Jens-Ulrik Rosholm, Jens Soendergaard, Lars F Gram, Jakob Kragstrup. (Denmark)
- 83 **A Study of Incidence of Pancytopenia in Patients Taking Leflunomide Alone or with Methotrexate [378]**
John McEwen, Richard L Hill, Patrick M Purcell, Lisa J Calcino, Cathy G Riley. (Australia)
- 84 **Anti-Hypertensive Drug Use Amongst Men with LUTS/BPH [379]**
Annie Hutchison, Richard DT Farmer. (United Kingdom)
- 85 **Analysis of Antipyretic Prescriptions to Children Aged 12 Years or under in French Office Based Medical Practice [380]**
Annie Pierre Jonville-Bera, Bruno Giraudeau, Jean Deline, Claudine Blum-Boisgard, Elisabeth Autret-Leca. (France)
- 86 **Challenges in Measuring Improved Appropriateness of Oral Hypoglycaemic and Other Drug Use in Type 2 Diabetes in Primary Care [381]**
Judith M Mackson, Lynne McMartin, Sheena O'Riordan, Margaret Fitzgerald, Kylie Easton, Lynn M Weekes. (Australia)
- 87 **Drug Utilization by Retired People: Results from Postal and Domiciliary Surveys in Belo Horizonte / MG, Brazil [382]**
Andreia Q Ribeiro, Francisco A Acurcio, Suely Rozenfeld, Carlos H Klein, Cristiano S Moura, Celia Andrade. (Brazil)
- 88 **Clinical Guidelines and Feedback to GPs and Hospital Doctors Improves Prescription Habits [383]**
Kirsten Schaefer, Lars Onsberg Henriksen. (Denmark)
- 89 **How Should We Assess the Clinical Relevance of Guidelines in Primary Health Care? [384]**
Liselotte LvF von Ferber, Christian CvF von Ferber. (Germany)
- 90 **Drug Utilization by Children and Adolescents with Mental Retardation: A Unique Population Study [385]**
Hilde Tobi, Karin A Netjes, Erik Mulder, Tom Scheers. (Netherlands)
- 91 **Doping in Sports: Knowledge of Prohibited Substances by Community Pharmacists [386]**
Genevieve Durrieu, Marie Noyer, Jean-Louis Montastruc. (France)
- 92 **Evolution of Antidepressives Consumption in the Valenciana Community in the 2000-2002 Period [387]**
Encarna Cardo, Laura Monzon, Fernando Fernandez-Llimos, Maria Jose Faus, Amalia Ubeda. (Spain)
- 93 **Monitoring Drug Prescription for Attention-Deficit / Hyperactivity Disorder (ADHD) [388]**
Katrin Janhsen, Gerd Glaeske, Elke Scharnetzky, Christel Schick Tanz, Andrea Ludolph, Fegert Joerg. (Germany)
- 94 **Study of the Prescriptions for Obesity at Drugstores in Distrito Federal, Brazil [389]**
Rogerio Hoefler, Claudio Valdivino e Silva, Valdete A Melo, Ana Paula P Lima, Marcus Tolentino, Emilia V Silva, Carlos CF Vidotti, Mariana HM Cunha, Amanda A Ferreira. (Brazil)
- 95 **Consumption of Lipid-Lowering Agents in Hungary (1993-2003); Impact of Individual Economic Burden [390]**
Gyongyver Soos, Edit Kosik, Gabor Nagy. (Hungary)
- 96 **Self Medication with Antibiotics in Czech Republic [391]**
Retnosari Andrajati, Jiri Vlcek, Flora M Haaajer-Ruskamp. (Czech Republic)
- 97 **Drug Consumption during Late Pregnancy and in Post-Partum Period: A Comparative Study between Lactating and Non-Lactating Women [392]**
Aurelie Olanor, Isabelle Lacroix, Michel Rolland, Jean-Louis Montastruc, Christine Damase-Michel. (France)
- 98 **Drug Utilization Profile among Brazilian Elderly People [393]**
Carlos H Klein, Francisco A Acurcio, Suely Rozenfeld, Andreia Q Ribeiro, Cristiano S Moura, Celia Andrade. (Brazil)
- 99 **Use of Antilipemic Drugs in National Healthcare Group (NHG), Singapore [394]**
Boon Peng Lim, Benjamin KC Ong. (Singapore)
- 100 **Prevalence, Predictors and Outcomes of the Inappropriate Drug Prescribing in Frail Community-Living Elderly: Eastern European Country Study [395]**
Daniela Fialova, Eva Topinkova, Jiri Vlcek, Roberto Bernabei. (Czech Republic)
- 101 **Medicines Selection by Physicians and Patients in Armenia [396]**
Irina Kazaryan, Margarita Melikyan, Anahit Amirkhanyan, Naira Hovsepyan. (Armenia)
- 102 **Tramadol Prescribing Pattern among Italian General Practitioners: A Population-Based Study [397]**
Gianluca Trifirò, Emiliano Sessa, Giampiero Mazzaglia, Pierangelo Lora Aprile, Gino Cancian, Ovidio Brignoli, Claudio Cricelli, Achille P Caputi. (Italy)
- 103 **Drug Use and Information Sources in Rural Areas in Lithuania /Results Based on Investigations in Alytus Region/ [398]**
Jurga Saskovaite, Romaldas Maciulaitis. (Lithuania)
- 104 **Study on Utilization of Drugs for Peptic Ulcer [399]**
Shengxin Chen, Lin Ma, Xiaofang Chen. (China)
- 105 **Determinants of Medicine Use in a Swedish Primary Health Care Practice Population [400]**
Ahmad Al-Windi. (Sweden)
- 106 **Quantitative Assessment of the Prescribing in the Teaching Hospital Using the Methodology Drug Utilisation DU90% in Two Consequent Years [401]**
Rachel Pipalova, Jiri Vlcek, Karel Macek. (Czech Republic)
- 107 **Use of Medicines by University Students [402]**
Ramona Mateos-Campos. (Spain)



- 108 A Patient Exposure Estimation Database [403]**
Joanne J Hunold, Mary Y Park, Daniel Fife. (United States)
- 109 Qualitative Evaluation of an Outcomes Guarantee Project for Lipid Lowering Drugs [404]**
Stephen R Chapman, Maria Allinson. (United Kingdom)
- 110 Methodological Issues in Evaluation of Interventions To Improve Hospital Antibiotic Prescribing: Measuring What and How? [405]**
Faranak Ansari, Dilip Nathwani, Craig Ramsay, Peter G Davey. (United Kingdom)
- 111 The Risk of Myocardial Infarction and Case Fatality in Users of Antidiabetics [406]**
Mette Lena Olsen, Taco BM Monster, Soren P Johnsen, Joseph K McLaughlin, Henrik Toft Sorensen, Hans H Lervang, Jorgen Rungby. (Denmark)
- 112 Diabetes Increases the Risk of Drug-Induced Torsades De Pointes: Analysis of Data from the French Pharmacovigilance Database [407]**
Atul Pathak, Jean-Francois Tournamille, Jean-Michel Senard, Jean-Louis Montastruc, Maryse Lapeyre-Mestre. (France)
- 113 Declining Blood-Pressure in Monica Populations - Is the Bell Curve Shifted Left or Flattened at the High End? Preliminary Analysis [408]**
Hugh Tunstall-Pedoe, John Connaghan, Richard A'Brook. (United Kingdom)
- 114 Risk of Adverse Birth Outcome for Pregnant Users of Pivmecillinam - A Population Based Cohort Study [409]**
Mette Vinther Skriver, Mette Norgaard, Lars Pedersen, Henrik C Schonheyder, Henrik Toft Sorensen. (Denmark)
- 115 Intrauterine Exposure to Folic Acid Antagonists and the Risk on Folic Acid Sensitive Congenital Anomalies [410]**
Willemijn M Meijer, Hermien EK de Walle, Wilhelmina S Kerstjens-Frederikse, Lolkje TW de Jong-van den Berg. (Netherlands)
- 116 An Evaluation of Norfloxacin Use during Pregnancy [411]**
Susan A Galea, Ann R Sweet, Kristine E Shields, Lynette E Etzel, Robert G Sharrar, Bengt-Erik Wiholm. (United States)
- 117 Pregnancy Incidence among Women with Inflammatory Skin Disorders [412]**
Lee Lanza, Elena Rivero, Carlos Fernandez, William A West, John D Seeger. (United States)
- 118 Maternal Use of Loratadine during Pregnancy and Risk of Hypospadias in Offspring: A Danish Nested Case-Control Design [413]**
Lars Pedersen, Mette V Skriver, Henrik T Sorensen. (Denmark)
- 119 Estimation of Variation in Congenital Anomaly Rate with Gestational Age [414]**
Jim M Slattery. (United Kingdom)
- 120 The Management and Outcomes of Patients Prescribed Rosiglitazone in Primary Care in England [415]**
Lynda V Wilton, Pipasha Biswas, Beate Barrera, Saad AW Shakir. (United Kingdom)
- 121 Does an Automated Thyroid Register Improve the Chronic Management of Hypothyroid Patients?: An Observational Study [416]**
Robert WV Flynn, Thomas M MacDonald, Andrew D Morris, Roland T Jung, Graham P Leese. (United Kingdom)
- 122 Patients' Opinions of Their Diabetes Control Is Associated with the Frequency of Self-Monitoring of Blood Glucose [417]**
Michiel J Storimans, Olaf H Klungel, Herre Talsma, Annemieke Floor-Schreuderling, Cornelis J de Blaey. (Netherlands)
- 123 Assessing the Association between Impaired Fasting Glucose, Diabetes, and Erectile Dysfunction: The Cansed Study [418]**
Steven Grover, Mohammed Kaouache, Ilka Lowensteyn, Sylvie Marchand, Louis Coupal, Isabelle Defoy, Emidio DeCarolis. (Canada)
- 124 Glycemic Effects of Hormone Replacement Therapy: Results of German National Health Surveys from 1984 to 1999 [419]**
Yong Du, Hans-Ulrich W Melchert. (Germany)
- 125 Incident Use of Thiazolidinediones Versus Metformin in Medicaid Managed Care Plans [420]**
Fadia T Shaya, James Y Shin, C D Mullins, Shonda Foster, Hugh O Fatodu. (United States)
- 126 Ophthalmological Events in Patients Taking Risedronate: Follow up Information in a Prescription-Event Monitoring Study [421]**
Beate Barrera, Lynda V Wilton, Saad AW Shakir. (United Kingdom)
- 127 The Management and Outcomes of Patients Prescribed Pioglitazone in Primary Care in England; Interim Results [422]**
Lynda V Wilton, Beate Barrera, Saad AW Shakir. (United Kingdom)
- 128 Results of a Post Marketing Surveillance Study in Japan Using Rh-Gh in Patients with Turner Syndrome without Epiphyseal Closure [423]**
Yoshie Kojima, Noriko Kobayashi, Noriko Nakamura, Kazuhiro Tsuchitani, Atsushi Watanabe, Ekaterina Koledova, Shohei Akita. (Japan)
- 129 Screening Logic To Establish the Incidence of Preventable Hypoglycemic Events in Acute Care [424]**
Almut G Winterstein, Thomas E Johns, Randy C Hatton, Eric I Rosenberg, Ricardo Gonzalez-Rothi, Wendy D Smith. (United States)
- 130 An Assessment of the Potential for Indication Bias in the Management of Chronic Health Conditions [425]**
Linda Levesque, Sophie Dell'Aniello, Samy Suissa. (Canada)
- 131 Incidence and Prevalence of Patients Receiving Insulin and Oral Antidiabetics; a Danish Register Based Study from 1991-2003 [426]**
Reimar W Thomsen, Gunnar L Nielsen, Hans-Henrik Lervang, Henrik T Sorensen. (Denmark)
- 132 The Hepatotoxicity of TZDS Observed in a Medical Center in Taiwan [427]**
Ling-Yu Liu, Churn-Shiouh Gau. (Taiwan)
- 133 Pilot Project for Education of Patients with Type 2 Diabetes by Pharmacists in Bulgaria [428]**
Valentina B Petkova, Guenka I Petrova, Anna V Peneva. (Bulgaria)
- 134 Statins and Cancer Risk: An Analysis of Clinical and Epidemiological Data [429]**
Miguel Gil, Claudio R Gimpelewicz, Michele Bortolini, Luis A Garcia, John O Logan, Yan Jia, Serguei Titaevski, Shepherd Mutyora, Christiane Sleboda. (Spain)
- 135 A Cohort Study To Monitor the Management and Outcomes of Patients Prescribed Carvedilol for Cardiac Failure in England [430]**
Lynda V Wilton, Beate A Bearra, Vanessa Marshall, Saad AW Shakir. (United Kingdom)
- 136 Association between Captopril, Other Antihypertensive Drugs and Risk of Prostate Cancer [431]**
Luis A Garcia Rodriguez, Ana Ruigomez, Saga Johansson, Mari-Ann Wallander, Goran Fritz, Kurt Svardsudd, Gunnar Ronqvist. (Sweden)
- 137 Irbesartan Associated Cholestatic Hepatic Change: A Randomized Controlled Clinical Trial [432]**
Hwa-Jung Kim, Hyun-Sook Hong, Nam-Kyung Choi, Seung-Mi Lee, Yooni Kim, Myung-Mook Lee, Byung-Joo Park. (Korea)
- 138 Assessing the Occurrence of Adverse Effects of Angiotensin-Converting Enzyme (ACE) Inhibitors in Patients 65 and Older Using the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (AERS) Known as Medwatch [433]**
Jennie Y Chou, John R Litaker, James P Wilson, Suneet D Gandhi. (United States)
- 139 Life-Threatening Ventricular Arrhythmia and Sudden Death in Users of Oxybutynin and Tolterodine [434]**
Kay Patterson, Iyue Sung, Gerry Faich, John D Seeger. (United States)
- 140 Responsiveness of the Self-Esteem and Relationship Questionnaire in Men with Erectile Dysfunction Treated with Sildenafil Citrate in a Double-Blind, Placebo-Controlled Trial [435]**
Joseph C Cappelleri, Michael P O'Leary, Stanley E Althof, Sandeep Duttgupta, Nancy Sherman, Arthur R Crowley, Richard Siegel, Li-Jung Tseng, Dale B Glasser. (United States)



- 141 Kidney Transplantation and Associated Immunosuppressive Therapy Impact on Patient's Quality of Life [436]**
Carla Teixeira de Barros, Jose Cabrita, Sabina de Geest, Philip Moons. (Portugal)
- 142 Evidence Based Review of Luteinizing Hormone Releasing Hormone (LHRH) Agonists in Metastatic Prostate Cancer [437]**
Michael Iskedjian, Thomas R Einaron, Michiel E Hemels, Neill Iscoe, Neil Fleshner, Colin Vicente. (Canada)
- 143 Lower Urinary Tract Symptoms in an Unselected Sample of Men Aged 55-75 Years - Association with Drug Use and Creatinine Levels [438]**
Christopher KT Farmer, Satish Jayawardene, Steven H Sacks, Richard DT Farmer. (United Kingdom)
- 144 Low-Dose Oral Contraceptive Use and Users' Characteristics: Unapproved Use for Endometriosis? - Japan Nurses' Health Study - [439]**
Shuku Fujimaki, Tomoko Kodama, Toshiharu Fujita, Shosuke Suzuki, Hideki Mizunuma, Takeshi Aso, Michael Reich, Alexander Walker, Kunihiko Hayashi. (United States)
- 145 Medication Use during the First Trimester of Pregnancy [440]**
Anick Bérard, Ariane Malouin, Driss Oraichi, Lise Gauthier, Annie Pellerin, Brigitte Martin, Sonia Boulanger. (Canada)
- 146 Adverse Drug Reactions in Pregnant Women [441]**
Isabelle Lacroix, Cendrine Cabou, Jean-Louis Montastruc, Christine Damase-Michel. (France)
- 147 Drugs and Breastfeeding: A French Collaboration in a Pharmacoepidemiology Study [442]**
Raphael Serreau, Christine Boissinot, Olivier Sibony, Aurelie Gilbert, Evelyne Jacqz-Aigrain. (France)
- 148 A 2004 Review of Pregnancy Outcome Datasources [443]**
Marianne C Cunningham, John G Weil, Janet Cragan. (United Kingdom)
- 149 Are Immunosuppressant Drugs a Risk or a Protective Factor for Urinary Leakage in Renal Transplantation: A Matched-Paired Nested Pilot Case-Control Study Using the Controlateral Renal Graft [444]**
Cyril Calvet, Catherine Rioc, Grégoire Robert, Jean-Marie Ferrière, Pierre Merville, Karin Martin. (France, Metropolitan)
- 150 A Patient Follow-Up Survey Program for LOTRONEX™ (Alosetron HCL): Assessing Compliance with the Risk Management Program [445]**
Elizabeth Andrews, Kelly Hollis, David Miller, Pat Tennis, Lee Bennett, Vanessa Ameen, Susan Gordon, Amy Heath, David McSorely, Suzanne Cook. (United States)
- 151 The Concept of "Brand Fidelity" Applied to Drug Uptakes by Populations: Examples on PPIs and H2RAs [446]**
Hani M Tamim, Marc Dorais, Sophie Rochon, Frederic Lavoie, Jacques LeLorier. (Canada)
- 152 An Epidemiologic Program for the Study of the Safety and Utilization of LOTRONEX™ (Alosetron HCL) in the US [447]**
David P Miller, Alexander M Walker, Jerry Avorn, Jerry Gurwitz, Suzanne F Cook, Andrew Feld, Pat Tennis, Lotronex Collaborative Research Group. (United States)
- 153 The Risk of Abdominal and Pelvic Surgery among Patients with Irritable Bowel Syndrome [448]**
J Alexander Cole, Jason Yeaw, Jennifer A Cutone, Braden Kuo, David Earnest, Zhiping Huang, Evelyn Rodriguez, Alexander M Walker. (United States)
- 154 Effect of Control of Confounding in the Estimation of the Proportional Reporting Ratio [449]**
David Sanchez Matienzo, Jordi Castellsague, Alejandro Arana. (Spain)
- 155 Determinants for Proton Pump Inhibitor Use in Patients with Gastroesophageal Reflux by Routine Care [450]**
Michael Kulig, Marc Nocon, Daniel Jaspersen, Joachim Labenz, Tore Lind, Wolfgang Meyer-Babellek, Manfred Stolte, Peter Malfertheiner, Stefan Willich. (Germany)
- 156 Utilization of Alosetron (Lotronex®) by the Elderly Prior to and Following the Initiation of a Risk Management Program [451]**
Rhonda L Bohn, Wolfgang C Winkelmayr, Jennifer M Polinski, Suzanne F Cook, Jerry Avorn. (United States)
- 157 Prevalence and Demographics of IBS Respondents: Results from a Large Web-Based Survey [452]**
S C Eaton, E B Andrews, K A Hollis, J S Hopkins, V Ameen, L R Hamm, A W Mangel, R E Williams, S F Cook. (United States)
- 158 Symptoms of Diarrhea-Predominant or Alternating IBS: An Exploratory Analysis [453]**
S C Eaton, A W Mangel, K A Hollis, V Ameen, L R Hamm, E B Andrews, R E Williams, S F Cook. (United States)
- 159 Characterization of IBS and Non-IBS Patients Using Mebeverine in Daily Practice [454]**
Wim G Goetsch, Maarten J ten Berg, Ron MC Herings. (Netherlands)
- 160 Monitoring of Population Risk of NSAIDs-Induced Gastropathy [455]**
Petra Fialova, Jiri Vlcek, Pavel Kohout. (Czech Republic)
- 161 Therapeutic Regimens for Peptic Ulcer Disease. A Treatment Cohort Study [456]**
Ana Paula Martins, Patricia Ferreira, Vera Gouveia, Antonio de Sousa Guerreiro, Jose Cabrita. (Portugal)
- 162 Drug-Induced Pancreatitis: About a Series of 49 Cases [457]**
Cécile Beden, Claire Guy, Michel Mallaret, Hugues Rousset, Michel Ollagnier. (France)
- 163 Ursodeoxycholic Acid in Belgium: The Prevalence of Allegedly Stable Biliary Diseases Is Not Obvious To Determine from Consumption Data [458]**
Marc Van de Castele, André De Swaef, Herman Beyers, Frederik Nevens, Gert A Verpooten. (Belgium)

END - Session B

WEDNESDAY, 25 AUGUST 2004 POSTER SESSION C

- 1 Perception of the Risk of Anti-Inflammatory Drugs in Pregnancy by Pregnant Women: A Survey among 250 Women in Midi-Pyrenees [513]**
Julie Christaud, Isabelle Lacroix, Alain Berrebi, Jean-Louis Montastruc, Christine Damase-Michel. (France)
- 2 The Incidence of Adverse Drug Events in Two Large Academic Long-Term Care Facilities: Higher Than Expected? [514]**
Jerry H Gurwitz, Terry S Field, James Judge, Paula Rochon, Leslie R Harrold, Cynthia Cadoret, Monica Lee, Kathleen White, Jane LaPrino, Janet Erramuspe-Mainard, Martin DeFlorio, Linda Gavendo, Jill Auger, David W Bates. (United States)
- 3 Disproportionality Analysis (DPA) To Explore Patient and Treatment Related Factors Associated with Adverse (AEs) [515]**
Nancy A Yuen, June S Almenoff, William DuMouchel, Xionghu Yang, Karol K LaCroix. (United States)
- 4 A Qualitative Exploration of the Underlying Causes of Medication-Related Admissions to a Teaching Hospital in the United Kingdom [516]**
Rachel L Howard, Anthony J Avery, Paul Bissell, Paul Howard. (United Kingdom)
- 5 Asking Doctors and Pharmacists To Talk about Their Involvement in Preventable Medication Related Hospital Admissions [517]**
Rachel L Howard, Anthony J Avery, Paul Bissell. (United Kingdom)
- 6 Indicators for Preventable Drug-Related Morbidity: Facilitating Changes in Practice? [518]**
Caroline J Morris, Judith A Cantrill, Anthony J Avery, Rachel L Howard. (United Kingdom)
- 7 The Association between Risk Factors and Warfarin Related Adverse Events: A Case-Crossover Study [519]**
Benjamin D Ofori, Peter T Donnan, Barclay M Goudie, Peter G Davey. (United Kingdom)
- 8 The "Travacalm" Episode [520]**
John McEwen, Jennifer J Robinson, Barry R Thompson, Patrick M Purcell, Larry F Kelly, Adrian S Krauss. (Australia)



- 9 **Parental Vaccine Safety Concerns: Experiences of Physicians** [521]
Gary L Freed, Sarah J Clark, Beth F Hibbs, Jeanne M Santoli. (United States)
- 10 **Using Stated-Preference Methods to Inform Pharmaceutical Risk Management** [522]
Elizabeth Andrews, Reed Johnson. (United States)
- 11 **Comparison and Analysis on Inclusion and Ratings of Potential Hepatotoxic Drugs among Major Drug Compendia in the United States** [523]
Jeff J Guo, Patricia Rozek, Kangsan Lammers, Oceana Vu. (United States)
- 12 **Renal Function Evaluation in the Very Old** [524]
Marie-Laure Laroche, Yves Nouaille, Jean-Pierre Charmes, Louis Merle. (France)
- 13 **Diabetes Mellitus Associated with Medication Use among Patients with Bipolar Disorders in a Managed Care Medicaid Population** [525]
Jeff J Guo, Paul E Keck, Raymond Jang, Hong Li, Dongming Jiang. (United States)
- 14 **Influence of Variables on the Time to Onset of Adverse Drug Reactions** [526]
Joyce J de Langen, Eugène P van Puijtenbroek. (Netherlands)
- 15 **Are Anti-Ulcer Drugs Associated with Gynaecomastia, Galactorrhoea, Breast Pain and Erectile Dysfunction?** [527]
Linda de Graaf, Eugène P van Puijtenbroek, Kees van Grootheest. (Netherlands)
- 16 **The Use of the MHRA/CSM Drug Analysis Prints** [528]
Ronald D Mann. (United Kingdom)
- 17 **Increasing the Effectiveness of Dyslipidemia Therapy by Showing Patients Their Calculated Coronary Risk: The Importance of Cardiovascular Age** [529]
Steven Grover, Ilka Lowensteyn, Louis Coupal, Mohammed Kaouache, Carl Brewer. (Canada)
- 18 **Hospitalisation of Elderly Patients Caused by Adverse Drug Reactions** [530]
Lionel Bertrand, Pascale Olivier, Marie Tubery, Dominique Lauque, Jean-Louis Montastruc, Maryse Lapeyre-Mestre. (France)
- 19 **Detecting Preventable Drug Related Morbidity in Ambulatory Care: A Systems Perspective** [531]
Brian C Sauer, Charles D Hepler. (United States)
- 20 **Poor Control of High Blood Pressure and Its Correlates in Older People: Community-Based Study in Scotland and China** [532]
Ruoling Chen, Li Wei, Roger Tavendale, Thomas M MacDonald. (United Kingdom)
- 21 **Intoxication by Medicinal Plants in Abidjan: Clinical, Epidemiological and Ethnobotanical Aspects** [533]
Mamadou Kamagate, Henri M Die-Kacou, Eric Balyssac, Jean-Claude Yavo, Potey T Daubret, Kakou A Kakou, Vamy M Gboignon. (France)
- 22 **Prescribing Behaviors of General Practitioners Visiting Elderly Patients at Risk of Iatrogenesis** [534]
Bruno Fantino, Nicolas Voirin, Françoise Fantino, Laurent Laforest, Neville Dickson, Eric Van Ganse. (France)
- 23 **Long Term Safety Follow-Up for Cancer Progression in Patients Who Had Participated in a Randomized Clinical Trial of a New Surgical Product** [535]
Joanna F Haas, Stephen Lake, PK Tandon, Lena Holmdahl. (United States)
- 24 **Risk Factors for Pregnancy among Isotretinoin Users** [536]
Carla M Van Bennekom, Y Kelly Cho, Allen A Mitchell. (United States)
- 25 **Prescription of Metformin and Renal Failure: Are the Present Recommendations Appropriate?** [537]
Michel M Lièvre, Laurent Vaur, Nathalie Genes, Michel Marre. (France)
- 26 **Errors in Medication Administration Are Not Accurately Reported in Long Term Care Facilities** [538]
Julie Vaillancourt, Jocelyne Moisan. (Canada)
- 27 **Benefit - Risk Quantitation Based on Patient-Reported Outcome Data from Women with Diarrheal Irritable Bowel Syndrome Treated with Alosetron or Placebo** [539]
John R Senior, Ted Guo. (United States)
- 28 **Risk Benefit Modeling: The Use of Stochastic Simulation for Safety Evaluations** [540]
Andrew Maguire, Felix M Arellano, Susana Perez-Gutthaus, Alejandro Arana. (Spain)
- 29 **Use of Voluntary Adverse Drug Reaction Reporting as a "Quality Indicator"** [541]
Ulf Bergman, Erik Eliasson, Birgitta Grundmark, Magnus Korsgren, Gunilla Sjoelin-Forsberg. (Sweden)
- 30 **Adverse Drug Reactions in Children: About One Year of Adverse Effects Collected by French Pharmacovigilance Centers** [542]
Françoise F Bavoux, Thierry M, Chena S, Vauzelle C Gardier. (France)
- 31 **The European Active Surveillance Study on Oral Contraceptives (EURAS-OC). Results after 50,000 WY of Observation** [543]
Lothar AJ Heinemann, Anita Assmann, Michael Lewis, Doerthe Kuehl-Habich. (Germany)
- 32 **Evaluation of Combined Oestrogen and Progestin or Progestin-Only Exposure of Women from Poitou-Charentes Area Who Presented a Thromboembolic Event: Transversal Study Conducting from May 2003 to November 2003** [544]
Sylvie Favrelière, Claire Lafay, Marie-Christine Pérault. (France)
- 33 **Cross-Over Cohort Study of Incident VTE in Women Exposed to Cyproterone in UK Primary Care** [545]
Jane NS Moseley. (United Kingdom)
- 34 **The Risk of Venous Thromboembolism Associated with Cyproterone Acetate in Combination with Ethinylloestradiol - An Update** [546]
Helen E Seaman, Corinne S de Vries, Richard DT Farmer. (United Kingdom)
- 35 **Modeling Invasive Meningococcal Disease and the Impact of Vaccination** [547]
J Jaime Caro, Denis Getsios, Jörgen Möller. (United States)
- 36 **Macrophagic Myofasciitis (MMF): An Exploratory Study To Assess Specificity of Clinical Patterns and Vaccines Exposure** [548]
Annie Fourier-Reglat, Romain Gherardi, Patrick Cherin, Jacques Ropers, Costagliola Dominique, Daniel Levy-bruhl, Philippe Malfait, Nathalie Lechevallier, Carmen Kreft-Jais. (France)
- 37 **Serious Adverse Events Following Smallpox Vaccination among U.S. Civilians** [549]
John Iskander, Christine G Casey, Martha Roper, Xiao-Jun Wen. (United States)
- 38 **A Comparison of Coded Case Definition Criteria with Narrative Symptom-Text in the U.S. Vaccine Adverse Event Reporting System** [550]
Katrin S Kohl, Many Magnus, Robert Ball, Robert P Wise, Neal A Halsey, Thomas A Farley. (United States)
- 39 **Inadvertent Rubella Vaccination during Pregnancy: Review of Reports to the U.S. Vaccine Adverse Event Reporting System (VAERS), 1991-2003** [551]
Angela Calugar, Vitali Pool, Susan Reef, Weigong Zhou, Robert T Chen. (United States)
- 40 **Adverse Events after Inactivated Influenza Vaccination in Children under Age 2 Years: Analysis of the Vaccine Adverse Event Reporting System, 1990-2003** [552]
Ann W McMahon, John K Iskander, Penina Haber, Soju C Chang, E Jane Woo, M Miles Braun, Robert Ball. (United States)
- 41 **Transient Bulging Fontanelle after Vaccinations: Reports to the U.S. Vaccine Adverse Event Reporting System** [553]
Stephen B Freedman, John Reed, Dale R Burwen, Robert P Wise, Amy Weiss, Robert Ball. (United States)
- 42 **Reports of Elective Termination of Pregnancy (ETP) in the Vaccine Adverse Event Reporting System (VAERS): 1990 - 2003** [554]
Soju Chang, Emily Jane Woo, Dale R Burwen, Robert P Wise, Robert Ball, M Miles Braun. (United States)
- 43 **Positive Re-Challenge Reports Following Hepatitis B Vaccination in Adults, Vaccine Adverse Event Reporting System (Vaers), USA, 1995-2003** [555]
Penina Haber, Weigong Zhou, English Bullard, the VAERS Team. (United States)
- 44 **Inadvertent Administration of Measles Vaccine in Early Infancy: A Review of Safety Data in the U.S.** [556]
Vitali Pool, Michelle Russell. (United States)



- 45 **Reports of Brachial Neuritis in the Vaccine Adverse Event Reporting System (VAERS), United States, 1991 - 2003** [557]
Weigong Zhou, Vitali Pool, Robert T Chen. (United States)
- 46 **Use of a Medication Identification Booklet for OTC Drug Reporting in a Case-Control Study of Birth Defects** [558]
Martha M Werler, Sonia Hernandez-Dias, Carol Louik, Jane E Sheehan, Allen A Mitchell. (United States)
- 47 **Issues around Psychometrics of the Portuguese Version for Portugal of the ADDQoL** [559]
Filipa Costa, José Pedro Guerreiro, Brenda Madureira. (Portugal)
- 48 **Validation of a Measurement Scale: The Example of a French Adverse Drug Reactions' Preventability Scale** [560]
Pascale Olivier, Jacques Caron, Françoise Haramburu, Jean-Louis Imbs, Annie-Pierre Jonville-Bera, Georges Lagier, Catherine Sgro, Thierry Vial, Jean-Louis Montastruc, Maryse Lapeyre-Mestre. (France)
- 49 **A Comparison of Interviewer Versus Automated Telephone Administration for Ascertaining Sensitive Data** [561]
Suzanne L West, Robert Agans, William Kalsbeek, Michael Steinbuch. (United States)
- 50 **Cluster Analysis of the I-PSS as a Measure of Change Following Treatment for LUTS/BPH** [562]
Annie Hutchison, Richard DT Farmer. (United Kingdom)
- 51 **Causality Assessment of Events Reported within an Observational Study** [563]
Francoise Haramburu, Ghada M Miremont-Salame, Abdelilah Abouelfath, Anne Laribiere, Hadrien Reyre, Ludovic Liege, Nicholas D Moore, Bernard Begaud. (France)
- 52 **Graphs in Pharmacoepidemiology - Can They Be Improved?** [564]
Charles H Goldsmith. (Canada)
- 53 **A Review of Systematic Reviews in Postmarketing Drug Safety** [565]
Jose G Orozco-Diaz, Howard Schachter, David Moher, Vicky Hogan, Connie Barrowclough, Ariel E Arias. (Canada)
- 54 **Confounding Bias Due to Subject Withdrawals in a Randomized Controlled Trial with an Intent-To-Treat Analysis** [566]
H Michael Arrighi, David A Brown. (United States)
- 55 **Effects of Cyclooxygenase-2 Selective Inhibitors, Rofecoxib and Celecoxib, and of NSAIDs on Esophageal Cancer** [567]
Marc Y Bardou, Alan N Barkun, Joumana Ghosn, Marie Hudson, Elham Rahme. (France)
- 56 **Are Cox-2 Selective Inhibitors Preferentially Prescribed in Patients on Aspirin Therapy?** [568]
Mary Teeling, Kathleen Bennett, John Feely. (Ireland)
- 57 **Coxibs: Evolution of Prescription's Behaviour in France** [569]
Julie Biga, Florence Taboulet, Maryse Lapeyre-Mestre, Robert Bourrel, Jean-Louis Montastruc. (France, Metropolitan)
- 58 **Methodological and Logistical Aspects of the Cadeus (Cox-2 and NSAIDs Description of Users) Study** [570]
Fanny Depont, Annie Fourrier-Reglat, Cecile Droz, Michel Amouretti, Yvon Merliere, Pierre Fender, Patrick Blin, Bernard Begaud, Nicholas Moore. (France)
- 59 **Risk of Acute Cardiac Events among Patients Treated with Cyclooxygenase-2 Selective and Non-Selective Nonsteroidal Antiinflammatory Drugs** [571]
David J Graham, David Campen, Craig Cheetham, Rita Hui, Michele Spence, Wayne A Ray. (United States)
- 60 **Upper Gastrointestinal Adverse Drug Reactions and Selective Cyclo-Oxygenase-2 Inhibitors (Celecoxib and Rofecoxib): A Case / Non-Case Study in the French Pharmacovigilance Database** [572]
Stephanie S Lugardon, Maryse Lapeyre-Mestre, Jean-Louis Montastruc. (France)
- 61 **Costs of Coxibs, Nonselective Nsaids and Concomitant Gastroprotective Agents among Patients Covered by the Régime Général D'assurance-Médicaments in Quebec** [573]
Elham Rahme, Isabelle Chabot, Youssef Toubouti, Jacques LeLorier. (Canada)
- 62 **Therapy Switching and Associated Costs in Patients on Selective Cox-2 Inhibitors and Nonselective NSAIDs in an Elderly Population in Quebec, Canada** [574]
Elham Rahme, Youssef Toubouti, Elke Hunsche, Isabelle Chabot. (Canada)
- 63 **Gastrointestinal Safety and Vioxx Effectiveness in Patients at High Risk for Gastric Injury** [575]
Stephane Bissonnette, Emmanuelle Denis, Yola Moride, John Sampalis. (Canada)
- 64 **Use of Selective Cox-Inhibitors in High Risk Patients: Possible Effect of Reimbursement on Adverse Events** [576]
Steinar Madsen, Stian Bjerke, Harald Liselvand, Pernille Harg. (Norway)
- 65 **Prospective Analysis of GP Database: Comparing Treatments Following First Consultation for a Symptomatic Hip or Knee in Elderly People** [577]
Louise Linsell, Mary Thompson, Jill Dawson, Krina Zondervan, Peter Rose, Tony Randall, Andrew Carr, Ray Fitzpatrick. (United Kingdom)
- 66 **Effectiveness of Lipid-Lowering Therapy in Primary Care in France** [578]
Eric Van Ganse, Michel Bertrand, Philippe Moulin, Thierry Souchet, Gerard de Pourville. (France)
- 67 **Cost-Effectiveness Analysis of Escitalopram in the Treatment of Major Depressive Disorder in Austria** [579]
Michiel EH Hemels, Siegfried Kasper, Evelyn Walter, Thomas R Einarson. (France)
- 68 **Cost-Effectiveness of Nesiritide Versus Dobutamine in Patients with Acutely Decompensated Heart Failure** [580]
Tobias Gerhard, Issam Zineh, Abraham G Hartzema, Almut G Winterstein. (United States)
- 69 **Predictors of Thirst and Interdialytic Weight Gain in Hemodialysis Patients: A Cross-Sectional Analysis** [581]
Shih-Chen Kuo, Junne-Ming Sung, Yea-Huei Yang Kao, How-Ran Guo, Szu-Yuan Lee, Jeng-Jong Huang. (Taiwan)
- 70 **Cost-Effectiveness of Screening Albuminuria Subsequent Treatment with Fosinopril To Prevent Cardiovascular Events. Pharmacoeconomic Analysis for Prevend-It** [582]
Jarir Atthobari, Folkert W Asselbergs, Paul E de Jong, Lolkje TW de Jong van den Berg, Maarten J Postma. (Netherlands)
- 71 **Mechanical and Allergic Adverse Events Related to Central Vascular Catheters: Epidemiology in the Medicare In-Hospital Surgical Population, 2002** [583]
Roselie A Bright, Leonard Mermel, Chesley Richards, Deborah Yoder. (United States)
- 72 **Survey of Medical Healthcare Resource Use in Ambulatory Patients with Parkinson's Disease** [584]
Marco Cosentino, Emilia Martignoni, Donatella Michielotto, Daniela Calandrella, Giulio Riboldazzi, Claudio Pacchetti, Sergio Lecchini, Giuseppe Nappi, Gianmario Frigo. (Italy)
- 73 **Fibromyalgia: Survey of Global Fibromyalgia Management by French General Practitioners in 2003** [585]
Francis Blotman, Eric Thomas, Eric Myon, Yves Mainguy, Charles Taieb. (France)
- 74 **Fibromyalgia: Survey of Global Fibromyalgia Management by French Rheumatologists in 2003** [586]
Francis Blotman, Eric Thomas, Eric Myon, Jean Paul Caubere, Charles Taieb. (France)
- 75 **Fibromyalgia: Cross-Survey of Rheumatologists and General Practitioners Awareness and Knowledge of Fibromyalgia** [587]
Francis Blotman, Eric Thomas, Eric Myon, Etienne Andre, Charles Taieb. (France)
- 76 **Adverse Drug Reactions in Patients from a Defined Cohort of Elderly Admitted to an Emergency Ward** [588]
Anders Helldén, Maria Johansson, Mia von Euler, Lars Axelsson, Gunnar Öhlén, Bo Herrlin, Ulf Bergman. (Sweden)
- 77 **Epidemiology of Osteoporosis in the Netherlands (1993-2002)** [589]
Martien JM Panneman, Wim G Goettsch, Piotr Kramarz, Ron MC Herings. (Netherlands)
- 78 **Fibromyalgia Syndrome: A French Epidemiological Survey** [590]
Charles Taieb, Jean Paul Caubere, Yves Mainguy, Etienne Andre, Eric Myon. (France)
- 79 **Fibromyalgia: A Socio-Demographic Profile of Patients Suffering from Fibromyalgia in France** [591]
Charles Taieb, Yves Mainguy, Jean Paul Caubere, Etienne Andre, Eric Myon. (France)

- 80 **A Registry-Based Study of Incidence of Hospitalisation for Interstitial Lung Disease (ILD) among Non Small Cell Lung Cancer (NSCLC) Patients in Sweden [592]**
Fredrik Nyberg, Anna Bergström, Saga Johansson, Göran Pershagen. (Sweden)
- 81 **A Registry-Based Study of the Incidence of Hospitalisation for Diverse Comorbidities among Non Small Cell Lung Cancer (NscLc) Patients in Sweden [593]**
Fredrik Nyberg, Anna Bergström, Saga Johansson, Göran Pershagen. (Sweden)
- 82 **Fibromyalgia: Survey of GPs Awareness and Knowledge of FMS [594]**
Francis Blotman, Eric Myon, Eric Thomas, Etienne Andre, Charles Taieb. (France)
- 83 **Fibromyalgia: Survey of Rheumatologists Awareness and Knowledge of Fibromyalgia [595]**
Francis Blotman, Eric Myon, Jean Paul Caubere, Eric Thomas, Charles Taieb. (France)
- 84 **Economic Evaluation of Primary Prevention of CVD Events with Statins [596]**
Silvia Bustacchini, Lorenzo G Mantovani, Pierfrancesco Ruffo, Desiree Bastarolo, Alessandro Battaggia, Mario Celebrano, Guido Danti, Sandro Giroto, Giuseppe Lombardo, Luigi Mezzalana, Verona Collaborative Study Group. (Italy)
- 85 **A Cross-Sectional Survey To Evaluate the Profile of Cardiovascular Risk in the Population: The Verona Collaborative Study [597]**
Silvia Bustacchini, Alessandro Battaggia, Gianstefano Blengio, Mario Celebrano, Guido Danti, Sandro Giroto, Roberta Joppi, Giuseppe Lombardo, Mersia Mirandola, Pierfrancesco Ruffo, Verona Collaborative Study Group. (Italy)
- 86 **Estimating the Reduction in Employee Disability Days by Modifying Cardiovascular Risk Factors: Developing a Markov Model [598]**
Louis Coupal, Steven Grover, Hanna Zowall, Jean-Eric Tarride. (Canada)
- 87 **A Meta-Analysis of Cancer Risk and Asthma Status Fails To Demonstrate an Association [599]**
Pat Tennis, Beth Sherrill, Carlos Fernandez, Evelyn Rodriguez. (United States)
- 88 **Increased Rates of Diagnosis for Hypertension or Dyslipidaemia in Patients Previously Identified with One of These Risk Factors: Data from the United Kingdom [600]**
Thomas M MacDonald, Steve V Morant, Eddy Mozaffari. (United Kingdom)
- 89 **Changes in Hypokalemia and Hyperkalemia Prevalence between 1991 and 2000 in the US According to Hypertensive Status and Treatment [601]**
Andrew Maguire, Maria del Mar Melero-Montes, Isabel Saez-Lloret, Cristina Varas-Lorenzo, Susana Perez-Gutthann. (Spain)
- 90 **A Retrospective Cohort Study of Diabetes Mellitus and Antipsychotic Treatment in the UK [602]**
Patrizia Cavazzoni, Kenneth Hornbuckle, Christopher Carlson, Frank DeLisle, Rebecca Noel, Alan Breier. (United States)
- 91 **Tertiary Use of Pharmacoeconomics Methods for Surveillance of Emerging Disease Outbreaks [603]**
Andy Stergachis, Bryant T Karras, Joe Fazio. (United States)
- 92 **Incidence of Non Hodgkins Lymphoma among Patients Exposed to Hepatitis B Virus [604]**
Marianne Ulcickas Yood, Charles Quesenberry, Jr., Dianlin Guo, Cary Caldwell, Karen Wells, Jun Shan, Gena Kucera, Mary Lou Skovron. (United States)
- 93 **Mean Preferences for Barthel Index Disability States in a Community Sample [605]**
Jamie Banks, Maribel Salas, Ann Netten. (United States)
- 94 **Utility in Patients with Stroke Related Disability [606]**
Sooyeon Kwon, Pamela W Duncan, Abraham G Hartzema, Sue-Min Lai. (United States)
- 95 **Estimating Annual Prevalence of Clinically-Significant Psoriasis in the General Practice Research Database (GPRD) [607]**
Martin M Crane, Jean M Hastie, Carla L Black. (United States)
- 96 **Clustering or Undue Association of Raised Blood Pressure and Blood Cholesterol in the Who Monica Project Population Surveys 1989-97 [608]**
Hugh Tunstall-Pedoe, Ruoling Chen, for the WHO MONICA Project. (United Kingdom)
- 97 **Prevalence of Individuals with Both Raised Blood Pressure and Raised Cholesterol in Who Monica Project Population Surveys 1989-97 [609]**
Hugh Tunstall-Pedoe, Ruoling Chen, Piotr Kramarz, for the WHO MONICA Project. (United Kingdom)
- 98 **Falls and Overactive Bladder: The Need for a Prevention Strategy [610]**
Robert Freeman, Sarah M Bridge, Julie Ann Dooley. (United Kingdom)
- 99 **Natural History of Chest Pain in General Practice Setting [611]**
Ana Ruigomez, Saga Johansson, Mari-Ann Wallander, Luis A Garcia Rodriguez. (Sweden)
- 100 **Natural History of Dyspepsia in General Practice: Incidence, Comorbidity and Risk Factors [612]**
Ana Ruigomez, Mari-Ann Wallander, Saga Johansson, Luis A Garcia Rodriguez. (Sweden)
- 101 **Alcohol and the Risk of Colorectal Cancer in the Korean Elderly: A Cohort Study [613]**
Hoi-Jeong Lim, Byung-Joo Park. (Republic of Korea)
- 102 **Quantitative Analysis of Class 1 Drug Reimbursement Submissions in Belgium [614]**
Philippe B Van Wilder, Gert A Verpooten, Jean Paul Degaute, Hugo Robays, Francis Aricx, Alain G Dupont. (Belgium)
- 103 **Rapid Monitoring of Drug Discontinuation Rates in Response to Restrictions in Drug Reimbursement [615]**
Colin R Dormuth, Sebastian Schneeweiss. (United States)
- 104 **An Economic Model To Assess the Cost Effectiveness of Treating Asthmatics with Gastroesophageal Disease [616]**
Harry B Nyanteh, Cameron K Schiller, Sonya Sednecor, Abraham Hartzema. (United States)
- 105 **Clinical and Economic Burden of Comorbid Hypertension and Dyslipidemia in the United States [617]**
Joshua S Benner, Allison A Petrilla, David S Battleman. (United States)
- 106 **The Social Need for New Drugs and the Pharmaceutical Market in 2003 [618]**
Carlos CF Vidotti, Lia LC Castro, Mariana HM Cunha. (Brazil)
- 107 **Comparison of 2 Methods for Capturing Drug Utilisation Data in Belgium [619]**
Philippe B Van Wilder, Andre De Swaef, Gert A Verpooten. (Belgium)
- 108 **Change in Prescribing Patterns of Hormone Replacement Therapy (HRT) Following the Publication of the Women's Health Initiative Study (WHI) [620]**
Briegen G Girvin, Therese M Rafferty, Michael R Stevenson, Dennis G Johnston. (United Kingdom)
- 109 **Clinical Background of Women Prescribed Tibolone or Combined Estrogen + Progestogen Therapies (CEPT): A UK MEDIPLUS® Study [621]**
Erica JM Velthuis-te Wierik, Paul T Hendricks, Mariette Boerstoeel-Streefland. (Netherlands)
- 110 **A Population-Based Study of the Effectiveness of Antiresorptive Agents on Risk Reduction of Fracture [622]**
Sylvie Perreault, Alice E Dragomir, Lucie Blais, Yola Moride, Michel Rossignol, Louis-Georges Ste-Marie, Julio Fernandes. (Canada)
- 111 **Chronic Venous Disease: Care Impact [623]**
Jean Jerome Guex, Eric Myon, Charles Taieb. (France)
- 112 **Chronic Venous Disease: Compliance with Treatment [624]**
Jean Jerome Guex, Eric Myon, Charles Taieb. (France)
- 113 **Chronic Venous Disease: Disease Age Impact [625]**
Jean Jerome Guex, Eric Myon, Charles Taieb. (France)
- 114 **Chronic Venous Disease: Through Body Mass Index [626]**
Jean Jerome Guex, Charles Taieb, Eric Myon. (France)



- 115 **Chronic Venous Disease: Patients Profile [627]**
Jean Jerome Guex, Charles Taieb, Eric Myon. (France)
- 116 **Chronic Venous Disease and Health Status [628]**
Jean Jerome Guex, Eric Myon, Charles Taieb. (France)
- 117 **Chronic Venous Disease and Specific Quality of Life [629]**
Jean Jerome Guex, Eric Myon, Charles Taieb. (France)
- 118 **Chronic Venous Disease and Depressive Symptomatology [630]**
Jean Jerome Guex, Eric Myon, Charles Taieb. (France)
- 119 **Postmarketing Surveillance of Severe Hematological Reactions to Drugs (Aplastic Anemia and Agranulocytosis): Potential Utility of an Empirical Bayesian Signal Detection Algorithm [631]**
Manfred Hauben, Lester Reich. (United States)
- 120 **Endotoxin-Like Reactions with Intravenous Gentamicin: Results from an Empirical Bayesian Data Mining Signal Detection Algorithm [632]**
Manfred Hauben, Lester Reich. (United States)
- 121 **Pancreatitis Reports with Atypical Antipsychotics: Retrospective Application of an Empirical Bayesian Statistical Signal Detection Algorithm [633]**
Manfred Hauben, Lester Reich. (United States)
- 122 **Postmarketing Surveillance of Severe Cutaneous Reactions to Drugs (Stevens Johnson Syndrome and Toxic Epidermal Necrolysis): Potential Utility of an Empirical Bayesian Signal Detection Algorithm [634]**
Manfred Hauben, Lester Reich. (United States)
- 123 **Adverse Events in Black-Box Warnings: Retrospective Application of an Empirical Bayesian Screening Algorithm [635]**
Manfred Hauben, Lester Reich. (United States)
- 124 **Safety Related Drug-Labeling Changes: Findings from Two Signal Detection Algorithms [636]**
Manfred Hauben, Lester Reich. (United States)
- 125 **Postmarketing Surveillance of Potentially Fatal Reactions to Oncology Drugs; Potential Utility of an Empirical Bayesian Signal Detection Algorithm To Drug Classes Likely To Qualify for Accelerated Approval and That Have a High Degree of Off-Label Use [637]**
Manfred Hauben, Lester Reich. (United States)
- 126 **Understanding the Role of the Report Date in Signal Detection Analyses [638]**
Matthew W Reynolds, Susan D Ross, Kyle Fahrback, Diana Frame, Catherine Cella. (United States)
- 127 **Understanding the Role of the Report Source in Signal Detection Analyses [639]**
Matthew W Reynolds, Susan D Ross, Kyle Fahrback, Diana Frame, Kimberly James. (United States)
- 128 **Pattern Detection for Celecoxib and Rofecoxib in the WHO Database [640]**
Andrew Bate, Niklas Noren, Roland Orre, Marie Lindquist, Ralph Edwards. (Sweden)
- 129 **Impact Analysis of Signals Detected from Spontaneous Adverse Reaction Reporting Data [641]**
Patrick C Waller, Emma L Heeley, Jane NS Moseley. (United Kingdom)
- 130 **Testing and Implementing Signal Impact Analysis in a Regulatory Setting: Results of a Pilot Study [642]**
Emma L Heeley, Patrick C Waller, Jane NS Moseley. (United Kingdom)
- 131 **Choosing the Measure of Relative Proportional Reporting in Quantitative Analyses of Spontaneous Reports [643]**
Alejandro Arana, Félix Arellano, David Sánchez-Matienzo, Susana Pérez-Guthann. (Spain)
- 132 **The Impact of Grouping Drugs by ATC Codes on Detecting a Signal from Japanese Spontaneous Reports [644]**
Yukari Kamijima, Eri Kawabe, Noriko Kubota, Tsugumichi Sato, Kiyoshi Kubota. (Japan)
- 133 **The European Active Surveillance Study on HRT Prescribing Practice, Benefits and Safety (EURAS) [645]**
Anita Assmann, Lothar AJ Heinemann. (Germany)
- 134 **Strategies To Recruit Women to an HRT Study Post Women's Health Initiative: [italic]The Women's Health and Hormone Study Experience[/italic] [646]**
Ilona Csizmadi, Linda S Cook, Christine M Friedenreich, Heather E Bryant, Gordon Fick, Anthony M Magliocco, Michael Pollak. (Canada)
- 135 **Prevalence and Costs of Difficult-To-Treat Depression in a Canadian Claims Database [647]**
Alki N Burdett, Charlotte C Gard, Christopher J Longo, David P Miller. (United States)
- 136 **Use of Nutritional Supplements and the Dietary Practices of a Group of South African Students: A Preliminary Study [648]**
Ilse Truter. (South Africa)
- 137 **Vasculitis Associated with Drug Use in Children in Italy [649]**
Giuseppe Traversa, Francesca Menniti-Ippolito, Roberto Da Cas, Liviana Da Dalt, Elisabetta Bressan, Carla Morando, Elena Falcon, Rossella Rossi, Paola Barabino, Salvatore Renna. (Italy)
- 138 **Cancer Risk among Users of Statins: A Population-Based Cohort Study [650]**
Soren Friis, Aslak H Poulsen, Soren P Johnsen, Joseph K McLaughlin, Henrik T Sorensen, Jorgen H Olsen. (Denmark)
- 139 **An Economic Analysis of the Impact of Highly Active Antiretroviral Therapy (HAART) Associated Dyslipidemia on Cardiovascular Risk and Life Expectancy [651]**
Steven Grover, Louis Coupal, Ilka Lowensteyn, Sylvie Marchand, Mohammed Kaouache, Hanna Zowall, Jayanti Mukherjee, Uchenna Iloeje. (Canada)
- 140 **FDA Adverse Event Reports on Statin-Associated Peripheral Neuropathy [652]**
Homa B Dastani, Jim Wilson. (United States)
- 141 **Adherence to Antiretroviral Therapy (HAART) in the Province of Quebec, Canada [653]**
Marc Dorais, Richard G Lalonde, Mariana Maier-Moldovan, Jacques LeLorier. (Canada)
- 142 **A Cohort of Cholinesterase Inhibitors (CHEI) USERS in the Province of Quebec, Canada [654]**
Marc Dorais, Fadi Massoud, Benedict Lescauwae, Frederic Lavoie, Jacques LeLorier. (Canada)
- 143 **What Do We Show and Who Does So? An Analysis of the Abstracts Presented at the 19th ICPE [655]**
Alejandro Arana, Elena Rivero, Toine CG Egberts. (Spain)
- 144 **A Literature Review on the Brazilian Published Output on Pharmaceutical Care in the past Five Years (1999-2003) [656]**
Maria Lourdes Oshiro, Lia Lusitana Cardozo de Castro. (Brazil)
- 145 **Compliance with Anti-Hypertensive Drugs through the Use of Reminder Cards [657]**
Jose P Guerreiro, Filipa Costa, Brenda Madureira, Ana C Miranda. (Portugal)
- 146 **Study of Adherence to Treatment Evaluated by the Doctor and Self-Reported by the Patient [658]**
Guitton Emmanuelle, Trenado Emmanuel, Maryse Lapeyre-Mestre. (France)
- 147 **The Association between Ovarian Cancer and Hormone Replacement Therapy: A Case-Control Study amongst Postmenopausal Women in UK Primary Care [659]**
Corinne S de Vries, Annie Hutchison, Richard DT Farmer. (United Kingdom)
- 148 **Comparative Assessment of Four Drug Interaction Databases [660]**
Agnes I Vitry. (Australia)
- 149 **The Risk of First Seizure Associated with Mefenamic Acid in Women of Reproductive Age [661]**
Daniel I Mines, Laura A Novelli. (United States)

END - Session C

